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ABSTRACT
DIET, PREBIOTICS, AND PROBIOTICS: EFFECTS ON GUT MICROBIOTA IN
OBESITY AND METABOLIC DISORDERS
THAMER ALJUTAILY
2019
Targeting gut microbiota with diet, prebiotics, and probiotics are emerging as a
promising intervention in the comprehensive nutritional approach to reducing obesity and
metabolic disorders. Recent human and animal studies suggest that such intervention can
promote health benefits by influencing the aspects of metabolism and immunity.
However, study of the multi-role association between the diet, the host and the
microbiota remains to be clarified. My dissertation attempts to clarify the problem of how
gut microbiota (taxonomic composition and predicted functional capacities) affects
obesity and metabolic disorders.
In chapter 2, I conducted a placebo-controlled intervention clinical trial to
evaluate effects of a synbiotic supplement containing Bifidobacterium and Lactobacillus
strains on the human gut microbiota in relation to changes in body composition and
metabolic biomarkers in obesity, followed the weight loss program eating plan (a lowcarbohydrate, high-protein dietary pattern with reduced energy intake). The results
obtained and bioinformatic analysis support the conclusion that the synbiotic supplement
used in this study modulates the human gut microbiota by increasing abundance of
beneficial microbial genera and that the supplement may also have beneficial effects on
metabolic parameters in obesity.

xvii

In chapter 3, I characterized the effect of dairy products (cow, goat, and camel
milk and fermented cheese and yogurt originated from cow milk and containing the wellestablished probiotic Clostridium butyricum) on taxonomic composition and relative
abundance of the mouse gut microbiota and body weight. The results obtained and their
bioinformatics analysis appear to support the conclusion that camel milk and the
probiotic cow cheese induce changes the mouse gut microbiota, which are associated
with the optimal weight gain in growing mice.
In chapter 4, I evaluate the effect of food at home (FAH) and food away from
home (FAFH) diets on human gut microbiota. Substantial work has been done to study
whether the FAH diet-induced microbial and immunity changes can protect mice against
diabetes. The results obtained and their analysis suggest that the FAH can help to reduce
risk of developing diabetes by increasing abundance of potentially beneficial microbial
species, T regulatory cells, and decreasing IL-17 producing cells and blood glucose
levels.
This dissertation explores a scope of studies on the effects of diet on gut
microbiota and health outcomes including obesity and metabolic disorders taking into
perspective diets such as food at home, dairy products, high-protein, low-carbohydrate,
prebiotic and probiotic. The main outcome of our studies is identification of an effective
and novel approach for the prevention and treatment of obesity and metabolic disorders
that is based on modulating the human/mouse gut microbiota and increasing abundance
of the microbial species that can be considered to be of benefit to their immune system
and host.
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CHAPTER 1. Introduction and Literature Review
The rising prevalence of obesity and metabolic disorders and its harmful health
consequences are of increasing global concern [1, 2]. Recent studies have implicated the
gut microbiota (a dynamic and complex population of microbes that live in the
gastrointestinal tract) in contributing to this epidemic [3-5]. However, advances in “next
generation” DNA sequencing have dramatically increased our capacity to study microbial
communities associated with human body habitats (microbiota) [6, 7]. Subsequent studies
revealed that gut microbiota influence caloric intake, intestinal absorption, energy
balance, and immunological status, therefore strategies aiming at modulating the
microbiota to control obesity and metabolic disorders are the focus of considerable
attention [8, 9]. Indeed, recent studies have shown that certain prebiotics and probiotics
(both diet-based processes that can be used to increase health of the host by enhancing
the composition of colonic microbiota) have been successful in promoting weight-loss in
diet-induced obesity or diabetes [10, 11].
Importantly, the gut microbiota provides the human host with a number of
benefits besides energy extraction, including vitamin synthesis and a reduction of lowgrade chronic inflammation associated with obesity and metabolic disorders [12, 13].
Therefore, a healthy and diverse gut microbiota is critical for the well-being of the host
[14, 15]. Consequentially, a gut microbiota intervention (either pre- or probiotics or a
synbiotic treatment) in individuals suffering a microbial dysbiosis from obesity or severe
diets may provide beneficial effects behind weight loss (Figure 1-1).
In these studies, human obese subjects and mouse model were used to test the
hypothesis that the specific diets, prebiotics and probiotics used in these studies will
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modulate the gut microbiota by increasing abundance of the beneficial microbial species,
T regulatory cells, and decreasing in inflammation-associated bacteria, IL-17 producing
cell populations, and the supplement may also have beneficial effects on body
composition and metabolic parameters in obesity. Three specific aims have been
designed to test this hypothesis.
AIM 1. To evaluate effects of the synbiotic supplement containing Bifidobacterium and
Lactobacillus strains on the human-gut microbiota in relation to changes in body
composition and metabolic biomarkers in obesity.
AIM 2. To characterize the effects of probiotic-enriched pasteurized milk, Greek-style
yogurt, and cottage cheese made from milk of different origins (cow, goat, and camel) on
the taxonomic composition of the mouse gut microbiota and body weight.
AIM 3. To study the effects of food at home and food away from home diets on human
gut microbiota. In addition, to study whether the food at home-diet-induced microbial and
immunity changes can protect mice against diabetes.

3

Figure 1-1. Importance of balanced nutrition and gut microbiota. There are shifts in the
composition of the microbiota (dysbiosis) whereby either the numbers of
Beneficial/Commensal are reduced and/or Harmful/Opportunistic are increased. Several
causes (i.e., dietary shifts, sedentary habits, high-fat diet, and antibiotic abuse) can trigger
this change and result in non-specific inflammation which can lead to diabetes, obesity,
and inflammatory diseases. Healthy diet and lifestyle, whole grains, dairy products and
prebiotic/probiotic supplements can reverse this inflammatory status to a healthy antiinflammatory environment.

4

Literature Review
The part (1.1.3) included in this literature review have been previously published in the
Cellular & Molecular Immunology:
Aljutaily, T., Consuegra-Fernández, M., Aranda, F., Lozano, F., & Huarte, E. (2018). Gut
microbiota metabolites for sweetening type I diabetes. Cellular & molecular
immunology, 15(2), 92–95. PMID: 28757611. Impact Factor (2018), 8.21; Ranking
(2018), 14/158 in Immunology.
1.1.1

Early mice studies
A causal link between gut microbiota and obesity was initially suggested based on

studies with germ free (GF) mice. Because gut microbiota has the capacity to ferment
otherwise-indigestible dietary compounds, and thus increase energy extraction from
foods, GF mice are leaner than conventional mice. However, they rapidly expand their fat
mass and increase insulin resistance after colonization with cecal microbiota from
conventional mice despite reduce food intake [16, 17]. Subsequent studies demonstrated
that colonization of GF mice with cecal microbiota from obese mice resulted in a greater
increase in body fat when compared with microbiota transplants from lean mice [18, 19],
thus demonstrating that an “obese microbiota” has an increased capacity to harvest
energy from the diet, and thus was responsible, and not just the consequence, of
metabolic disease and obesity. A more recent study where GF mice were colonized with
fecal samples obtained from adult female twin pairs discordant for obesity confirmed the
capacity of certain bacterial communities to increase total body and fat mass, as well as
obesity-associated metabolic phenotypes. Importantly, the study also demonstrated that
the induced metabolic disease was reversible when mice were exposed to a “lean
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microbiota” and dependent on the diet [20], thus confirming transmissible, rapid and
modifiable effects of diet by microbiota interactions and opening the door to microbiota
modification strategies as a therapy against obesity and metabolic disease.
1.1.2

Human gut microbiota
Human beings host trillions of microbes from all domains of life (eukaryota,

bacteria, virus and archaea) on multiple surfaces, with the highest density and diversity
located on the colon, where bacteria cells are present in concentrations of 109-1012 per ml
[21]. While the diversity of the gut microbiota is mind-blowing (averaging more than
1000 different species with an aggregate of approximately 0.5 million genes per human
host), up to 90% of the bacterial species belong to just 2 phyla: Firmicutes and
Bacteroidetes [22, 23]. Originally, a higher proportion of Bacteroidetes over Firmicutes
have been correlated with a leaner status both in mice and humans [24]. Recent studies,
however, focus on characterizing the microbiota at the species and strain levels, allowing
for finer associations between microbiota and weight. Despite the large inter-individual
(and even intra-individual) variation in the gut microbiota, it has also been suggested that
individuals can be assigned to one of just 3 different metagenomics profiles (called
enterotypes), dominated by either Bacteroides, Prevotella or Ruminococcus, of which
Bacteroides and Ruminococcus are often associated with a low-grade persistent
inflammation, obesity and metabolic disease [25, 26].
1.1.3

Gut microbiota metabolites and type I diabetes
Type 1 diabetes (T1D), also referred to as insulin-dependent diabetes mellitus, is a

debilitating disease that follows the destruction of pancreatic insulin-producing β cells by
autologous T-cells. T1D primarily affects children and has a strong genetic component,
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with >50 susceptibility loci identified, including HLA-DQβ chains [27]. However, the
striking differences between European regions with similar genetic backgrounds and a
sharp rise in T1D incidence in developed countries over the last several decades suggest
that environmental factor(s) also play a relevant etiopathogenic role [28]. Given the
accumulating evidence linking the gut microbiota to protection against metabolic diseases
[29], Mariño et al. recently tested the hypothesis that short-chain fatty acids (SCFAs),
which are the end products of fermentation of dietary fibers by anaerobic intestinal
microbiota, can protect genetically susceptible mice from developing T1D [30].
Interestingly, the authors found that diets enriched in acetate or butyrate (two of the main
SCFAs) can protect animals from developing diabetes through different and
complementary cellular mechanisms. Such findings significantly enhance our
understanding of the role of diet and gut microbiota in the development of autoimmune
diseases and indicate that the use of medicinal foods may be a cost-effective treatment
against T1D and other autoimmune diseases with a cellular component. Given that
current anti-T1D approaches (which focus on prevention or modulation of the adaptive
specific immune response against autoantigens) have been generally disappointing [31],
such a new and refreshing strategy has attracted a great deal of attention (reviewed in
Ref. [28]).
Over the last decade, an ever-growing body of evidence has established that the
gut microbiota is one of the most important epigenetic determinants of prevalent
metabolic disorders such as type 2 diabetes and metabolic syndrome [32]. Similarly,
accumulating experimental observations indicate that T1D incidence in non-obese
diabetic (NOD) mice is influenced by the microbial environment, thus indicating that the
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gut microbiota is involved in T1D development [33]. This concept has been well
illustrated by a recent report demonstrating that the interaction between the gut
microbiota and the host immune system was essential for the prevention and treatment of
T1D [34]. In their study, Wen et al. generated myeloid differentiation primary response
88 (MyD88)-deficient mice in a NOD background (NOD.Myd88−/−). MyD88 is a master
regulator of immune responses and is capable of detecting bacteria and other infectious
agents by binding to Toll-like receptors and initiating a pro-inflammatory cascade
dependent on nuclear factor kappa beta (NF-κB) activation. NOD.Myd88−/− mice kept
under specific-pathogen free conditions were completely protected against T1D
development, but this protection was dependent on commensal microbiota, as
NOD.Myd88−/− mice housed in germ-free (GF) conditions developed robust diabetes.
Importantly, when these animals were colonized with altered Schaedler’s flora, which is a
consortium of six bacteria that are normally found in the human gut, protection against
T1D was restored. Molecular analyses of cecal microbiota revealed that MyD88 ablation
correlates with changes in the microbiota composition, with a significant increase in
butyrate-producing Firmicutes, as well as Rikenellaceae and Porphoromadaceae.
SCFA (namely, acetate, butyrate and propionate) are the main metabolites of the
bacterial fermentation of dietary fiber and have been associated with anti-inflammatory
effects via the up-regulation of regulatory T (Treg) cells and the inhibition of histone
deacetylase (HDAC) activity [35]. Given the instrumental role of SCFA in intestinal
homeostasis, Mariño et al. compared the SCFA concentration in diabetes-prone NOD
mice and their diabetes-resistant NOD.Myd88−/− counterparts. Although the propionate
levels were similar between both mouse lines, the acetate and butyrate levels were much
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higher in the NOD.MyD88−/− animals, which suggested that T1D protection was
mediated by SCFAs. In addition, T1D-prone NOD mice under GF conditions developed a
more aggressive form of the disease, thus supporting the role of commensal bacteriaproduced metabolites as a defense mechanism against diabetes (Figure 1-2).

Figure 1-2. Main experimental approach revealing the specific mechanisms of acetate
and butyrate protection in T1D development. (a) NOD mice undergo exacerbated T1D in
germ-free (GF) conditions. Oral administration of acetylated high-amylose maize starch
(HAMSA) or butyrylated high-amylose maize starch (HAMSB) increased acetate or
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butyrate concentrations, respectively, which protected NOD mice from T1D development
via independent mechanisms. Whereas HAMSA administration reduced specific IGRP
(islet-specific antigen glucose-6-phospatase catalytic subunit-related protein) reactive
CD8+ T-cells and induced a reduction in MHC-I and CD86 expression, HAMSB
increased the Treg cell population. Splenic T-cells from NOD mice that were orally
treated with HAMSB, when transferred into immunodeficient NOD-SCID mice, reduced
T1D severity in receptor NOD-SCID mice. Fecal transplant of gut microbiota from NOD
mice fed the HAMSA/HAMSB diet into GF NOD mice transferred diabetes protection.
(b) NOD mice that express a transgene encoding the αβ TCR derived from a CD8+ T-cell
clone specific against IGRP (NOD8.3) undergo acute T1D. The HAMSA diet inhibits the
specific proliferation of IGRP reactive CD8+ T-cells NOD8.3 and, ultimately, T1D
progression.

In an effort to provide both a mechanistic explanation and to increase the

potential clinical relevance of their findings, Mariño et al. fed NOD mice with special
diets designed to release large amounts of specific SCFAs after bacterial fermentation. As
expected, mice fed acetylated high-amylose maize starch (HAMSA) showed higher
concentrations of acetate, whereas mice fed butyrylated high-amylose maize starch
(HAMSB) presented higher concentrations of butyrate. Notably, both diets induced local
and systemic increases in the corresponding SCFA levels, but had no effect on body
weight or food or energy intake. Confirming their hypothesis that bacterial metabolites
can protect genetically prone animals from developing T1D, animals fed either HAMSA
or HAMSB presented a significantly reduced incidence of diabetes. Mice fed a
combination of these diets demonstrated an even higher protection against diabetes,
suggesting different mechanisms of action for acetate and butyrate. This finding was
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further confirmed in experiments using NOD8.3 mice, which express a transgene
encoding the αβ T-cell antigen receptor derived from a CD8+ T-cell clone specific against
islet-specific antigen glucose-6-phospatase catalytic subunit-related protein (IGRP),
which is a major target of autoreactive T-cells in pancreatic β-cells [36]. Even in this
model of aggressive and rapidly progressing disease, a diet designed to release large
levels of acetate showed a protective effect, as evidenced by both a delay in diabetes
progression and a diminished percentage of IGRP-specific CD8+ T-cells (Figure 1-2).
The authors also found a remarkable reduction in the number of B cells from the
spleen and Peyer’s patches from NOD mice that were fed the HAMSA diet. Moreover,
B-cells from spleen from animals fed the HAMSA diet also expressed lower levels of
major histocompatibility complex class-I (MHC-I) and costimulatory CD86 molecules.
These results strongly indicate that impaired antigen presentation likely causes a
reduction in autoreactive CD8+ T-cells and concomitant protection against diabetes.
These results fully agree with the previous report from the same group showing that
cross-presentation by antigen presenting B-cells of islet-derived autoantigens drives the
expansion and differentiation of self-reactive CD8+ T-cells in the pancreatic lymph node
into effector cells, a critical process for the transition from clinically silent insulinitis to
overt diabetes [37].
Butyrate has been linked to an increase in the number and activation status of Treg
cells [38]. Because Tregs cells are known to play a critical role in controlling T1D [39], the
authors next tested the hypothesis that HAMSB-fed animals would have increased
numbers of Treg cells and would thus prevent autoreactive T-cells from inducing T1D. In
an elegant reverse protection approach, spleen T-cells from NOD mice fed with the
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different diets were transferred into severe combined immunodeficiency mice (NODSCID). Because SCID mice are depleted of B- and T-cells, the experiment allowed the
authors to study the direct effects of the individual diets on the donor T-cells. In this
rapidly progressing T1D model, the authors found that the adoptive transfer of spleen Tcells derived from animals fed the HAMSB (but not HAMSA) diet almost completely
protected host animals from diabetes development. Surprisingly, spleen T-cells obtained
from animals fed with the original high-amylose resistant starch (HAMS) were also
protective, albeit to a lesser extent. Further analysis showed that HAMSB-fed animals
promoted the conversion of CD4+ T-cells into Foxp3+ IL-10-producing (Treg) cells.
Although this result supports a putative role of Treg cells in butyrate-mediated protection
against diabetes, a formal demonstration that such Treg cells are indeed responsible for
ablating diabetes by inhibiting autoreactive T-cell proliferation was not provided (Figure
1-2).
Finally, the authors analyzed changes in the gut microbiota of animals fed with
the specialized diets. As expected, NOD mice fed the HAMSA and, to a lesser extent, the
HAMSB diets presented a higher percentage of Bacteroides—a genus that has been
linked with diabetes protection [34]. Importantly, fecal transplant of gut microbiota from
NOD mice fed with the acetate-rich HAMSA diet into GF NOD mice was sufficient to
elevate levels of acetate and transfer diabetes protection, thus further highlighting the
relevance of gut microbiota in T1D pathogenesis (Figure 1-2). However, from a
translational point of view, fecal transplants are associated with technical challenges and
an almost overwhelming physiological stress and social stigma [40]. Thus, future
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experiments should address whether individual bacterial species isolated from colonized
GF could also transfer diabetes protection.
Collectively, the data presented by Mariño et al. [30] highlight that acetate and
butyrate, which are two of the main products of bacterial fermentation, can provide
disease protection in a mouse model of autoimmune diabetes. Because each metabolite
acts through different molecular mechanisms (acetate reduces the proliferation of
autoreactive T-cells by minimizing B cell antigen presentation to T-cells, whereas
butyrate increases the number and activity of Treg cells), their additive effects could be
beneficial for controlling other immune-based disorders, particularly those of
gastrointestinal origin (for example, chronic inflammatory bowel diseases such as
Crohn’s disease or colitis ulcerosa). Investigations in this regard are warranted and are
largely fueled by the increasingly accepted role of the gut microbiota in the development
and control of several metabolic diseases, as well as the growing interest in the potential
use of prebiotics and probiotics as therapeutic tools to improve gut integrity [41]. The
sheer complexity and inter-personal variation of the gut microbiota make any attempt to
manipulate it extremely challenging. However, this study opens the door for the use of
medicinal food (nutraceuticals) that is rich in bacterial metabolites as a promising and
cost- effective treatment against T1D and other autoimmune diseases.
1.1.4

Association between gut microbiota and metabolic health
The gut microbiota of lean and obese individuals was first compared in a seminal

study by Ley, et al. in 2006 [42] using 16S rRNA sequencing (the 16S rRNA gene is a
section of prokaryotic DNA found in all bacteria that codifies for the small subunit of the
ribosome and sequencing of its hypervariable regions allows us to identify bacterial
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species at various taxa levels). Sequencing of DNA extracted from fecal samples
demonstrated that obese individuals present a higher level of Firmicutes and lower level
of Bacteroidetes than lean individuals [42], which validated previous murine studies [43].
Subsequent studies revealed that the gut microbiota composition of obese individuals is
less diverse than in lean individuals [44, 45]. However, different results have also been
reported [46, 47], and debate continues regarding the significance of the Firmicutes and
Bacteroidetes proportion. Recent meta-analysis study has shown that the microbial
changes associated with obesity are not based on phylum differences, but rather are the
consequence of numerous small differences within the bacterial community [48].
Therefore, it is important to understand the overall composition of the gut microbiota
rather than simply the proportion of Bacteroidetes to Firmicutes. Importantly, not only
different bacteria, but also the metabolites they produce (postbiotics) can play a role in
obesity and metabolic syndrome [49]. For example, patients with type-2 diabetes have
reduced levels of SCFA-producing bacteria [50, 51], and some SCFAs (e.g., butyrate)
facilitate enhanced insulin sensitivity and fatty-acid oxidation in muscle as well as
increased satiety [52, 53]. Because obesity has been linked to less diverse gut microbiota
composition than in lean individuals, it may be important to increase its diversity, and
nutritional approaches to do so (via combined probiotic with prebiotic consumption) can
promote weight loss.
According to Brown, et al. there is a relationship between the gut microbiota and
diseases such as obesity and type 2 diabetes, which are mainly influenced by diet taken
[54]. They indicated that since gut microbiota participates in the body’s metabolism,
energy balances and metabolism of glucose are influenced. Obesity is linked with
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dysbiosis (a microbial imbalance) in the intestinal of human beings, therefore there is a
high propensity that diet influences dysbiosis and host metabolism [55, 56]. Therefore,
gut microbiota has vital roles in host metabolism as well as directing immune system [57,
58]. Other studies have linked gut microbiota with type 2 diabetes since it has been
asserted to resist insulin [59]. Therefore, gut microbiota has the propensity of influencing
type 2 diabetes in collaboration with or obesity.
1.1.5

Current strategies to modulate the gut microbiota to treat obesity and

metabolic disorders
Lifestyle modifications are an important part of obesity prevention and
management. Unfortunately, too often they fail to consistently lead to appreciable weight
loss [60]. Other alternatives such as pharmacotherapy and surgery can be indicated for
short term weight management in severely obese patients, but significant risks and high
price prevent them from being the treatment of choice for a majority of patients.
Encouraged by its efficacy to treat Clostridium difficile infections [61], fecal gut
microbiome transplantation (GMT) has been proposed as an alternative for patients that
fail to manage weight under other treatments [62]. However, the use for GMT as a
treatment for metabolic diseases is only experimental and security concerns as well as
psychological stress makes it unappealing [63]. Therefore, it is clear that new approaches
are needed to complement existing ones.
Erejuwa, et al. indicate that gut microbiota have numerous roles that comprise of
digestion, metabolism, and the prevention of pathogens [64]. The authors indicate that
there have been a rise in prevalence of metabolic disorders such as obesity, and type 2
diabetes. Therefore, in recent times there has been numerous studies that have linked gut
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microbiota with some pathophysiological and the role that gut microbiota plays in
metabolic disorders [65, 66]. Since there is a close association of gut microbiota and the
metabolic disorders such as obesity, there have been numerous ways that have been
suggested to modulate gut microbiota so as to manage the metabolic diseases. Some of
the modulation suggested comprise of probiotics and probiotics [64, 67]. For instance,
some scientific study on mice found that administering prebiotic supplements in obese
mice have the propensity of improving the tolerance of glucose and the content of muscle
content [68].
1.1.6

The role of probiotics and prebiotics in health enhancement
Other studies have suggested that probiotics and prebiotics can be used to enhance

health of individuals and mitigate chronic diseases such as diabetes type 2 and obesity
[49, 69]. Prebiotics and probiotics are diet-based processes that can be used to health of
the host by enhancing the composition of colonic microbiota. For instance, prebiotic and
probiotic have been found to vary the overall composition of the gut microbiota if the
dietary intervention are carried out. Some studies have indicated that prebiotics are
dietary substrates that can enhance proliferation or activity of the bacteria that are present
in the original colon. Prebiotic in the recent times have been defined as “selectively
fermented ingredients that result in specific changes, in the composition and/or activity in
the gastrointestinal (GI) microbiota, thus conferring benefit(s) upon host health” [70].
Numerous studies have validated the concept of prebiotic and the role that prebiotics play
in minimizing the risk of bowel obstruction and other systematic diseases [71, 72].
Specifically, it was found that prebiotics have a strong potential of protecting human
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beings from various chronic diseases or conditions such as type 2 diabetes and obesity
[72, 73].
1.1.7

The role of diet in gut microbiota and health outcomes
A wide body of research has been explored to investigate the role of diet on gut

microbiota and the resulting health outcomes especially type 2 diabetes and obesity
among with the health complications linked to these diseases. Conlon & Bird (2014)
investigated the impact of diet and lifestyle on gut microbiota as well as the human health
in a study that recognizes that diet is an important factor in regulating the composition
and metabolic activity of gut microbiota [69]. Gut microbes are known to produce
numerous number of bioactive compounds that can impact the health of an individual,
therefore dietary means such as the consumption of fibers can be very vital in
maintenance of a healthy gut microbiota population [69, 74]. Gut microbial have the
capability of producing numerous products, and some of the products produced have
adverse effect on the health of human beings [75]. The impact of diet in the gut
microbiota and health has been vastly studied, for instance diets rich in fiber have been
found to promote and maintain bowel health due to the fact that they increase digested
mass [69]. Additionally, dietary fat have been found to influence the structure as well as
the metabolic activity of gut microbiota, and this phenomenon has been associated with
obesity [69, 76]. Studies indicate that high fat diets triggers circulation levels of bacteria
that are associated with lipopolysaccharide (LPS), and this is can be attributed to an
enhancement of intestinal permeability [77].
Graf, et al. (2015) indicated how important the human gut microbiota is, and the
manner in which it is influenced by various factors such as diet [78]. The authors
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indicated that nutrients that are indigestible for human enzymes such as fiber provides
substrates for the intestinal microbial metabolism. The fact that bacteria are responsible
for triggering the fermentation of different substrates, complex diet can either promote or
inhibit growth for some phylotypes [79]. For instance whole grain products are mainly
characterized with high content of fiber, and the fact that the human body doesn’t have
any enzymes that can digest their structures they reach the colon where they are
metabolized by the microbiota, which in turn inhibit the growth of different bacterial
groups [80, 81]. The composition of the human gut microbiota can be argued to be stable
and any short term dietary intervention does not seem to change the composition of the
microbiota. Nonetheless, the microbial gene expression and consequently the functional
profiles seems to adopt to changes in diet more easily [80, 82].
Heinritz, et al. (2016) conducted a research to ascertain the impact of high-fat or
high fiber on intestinal metabolic markers where they used pigs in their study [83]. The
main reason why the pigs were used is because they have the same dietary changes
similar with those of humans. The study ascertained that there was a hypotrophic effect
on the high-fat (HF) diet compared to low-fat (LF) diet. Diets rich in fiber have also been
reported to be trophic to their ability to ferment easily, thereby enhancing production of
SCFA that stimulates epithelial cell proliferation [83, 84]. Metabolic activity of gut
microbiota is mainly influenced by the production of different microbial metabolites, for
instance consumption of LF diet have the propensity of increasing the concentration of
butyrate and acetate in cecum and colon [83, 85]. Therefore, the role of diet in regard to
the composition and the metabolic activity of gut microbiota is very important since it has
the propensity of influencing health [69]. Diet is a vital aspect that shapes gut microbiota,
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and this means that diet and nutritional components should be taken into consideration
since they can trigger diseases such as obesity [83]. For instance, some studies have
indicated that harmful and pathogenic gut microbes are linked to diseases such as obesity,
and this is because some diet causes imbalances of gut microbiota [56, 79]. Thus,
different nutrients have different components that impacts gut microbiota, which in turn
influences aspects such as the metabolic activity.
According to previous research on the impact of diet on health-type 2 diabetes
and obesity, it is worth to note that the adverse metabolic effects of ‘western’ style of diet
characterized by high sugar and salt levels as well as highly processed foods go beyond
the macronutrients [86]. For instance, artificial sweeteners and emulsifiers have been
linked to the development of metabolic syndrome aspects through the modulation of the
microbiota mice [87, 88]. According to the findings from a study conducted by McGill, et
al. there was evidence of insulin resistance when hosts fed on high doses of artificial
sweeteners after only 7 days of intake of the sweetener [89]. These findings provide
insights into the conclusion that there is scientific evidence to suggest that artificial food
additives, especially those with high sugar level contribute immensely to development of
metabolic disease by disturbing the microbiota. This gives rise to the development of
diseases such as type 2 diabetes and obesity. Worth noting is the insights provided by the
analysis of the differences in susceptibility of the western countries and those in
developing countries especially in Africa. For instance, western dietary trends are
historically characterized by low levels of dietary fiber based on plants, which is an
essential fuel for microbiota [90, 91]. As such, the inclusion of abundant level of
nutrients that negatively impact the microbiota in the absence of dietary fiber creates a
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situation that makes it easy to understand metabolic diseases as such dietary consumption
is the leading causes of diabetes and obesity.
1.1.8

The role of gut microbiota in the regulation of fat storage and homeostasis
Research shows evidence of the influence of diet in the gut microbiota and health

especially diabetes and obesity. These two health complications are evidenced by the role
of the gut microbiota in the regulation of fat storage and homeostasis [12, 92]. According
to a study conducted by Chassaing, et al., (2015), it is reported that gut barrier
dysfunction and microbiota alteration are resultant are induced by two dietary
emulsifiers; polysorbate-80 and carboxymethylcellulose in mice [93]. As a result, the
mice experienced major metabolic disorders, low-grade inflammation, weight gain and
rise in blood sugar level. While it is not conclusive that intake of ‘western’ processed
foods in uniquely responsible for the increase in cases of inflammatory diseases and
obesity, there is no doubt that consumption of several of such compounds could play a
major role in inducing worse metabolic health and low-grade inflammation in organisms
that may be susceptible to metabolic disease. A large body of literature relate to the
comprehension of the role of gut microbiota in influencing metabolism, absorption and
storage of calories after digestion [94, 95]. Research suggests that gut microbes alter the
manner in which the human body reacts to elements of diet and nutrition to influence
metabolism. However, there is lack of conclusive evidence on the mechanisms that
underlie this process as they are highly complex to reconcile. Nevertheless, emerging
trends in the field suggests that obesity is linked to reduced diversity of the gut
microbiota [96, 97].
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1.1.9

Gut microbiota and sources of dietary fats
Most of the experiment that evaluate the role of diet in the gut microbiota and

type 2 diabetes, obesity use western type of diet, which is full of processed foods and
devoid of fibers [98]. Such foods are filled with calories from the saturation of sucrose
and fat, and they illustrate that gut microbiota significantly regulates the occurrence of
obesity through additional pathways [99, 100]. For instance, research shows that germfree mice that have been fed with a diet that is low in sucrose and high in fiber show
partial protection from obesity, primarily microbiota-dependent obesity [101]. This type
of protection is withdrawn upon the omission of sucrose from the diet. For purposes of
this analysis, it is very important that the source of the dietary fats be understood. This is
because the two types of dietary fats; saturated and unsaturated deliver diverse influence
on the gut microbiota [102, 103]. Moreover, the modified microbiota caused by intake of
unsaturated fats plays a role in protecting human beings from weight gain resulting from
such feeding [76, 104]. Subsequently, weight gain becomes inevitable with consumption
of unsaturated fats than when saturated fats are consumed. The review of previous
findings suggest that fats and simple carbohydrates could result in unexpected impacts on
the metabolism of users of such diet through microbiota.
1.1.10 Link between gut microbiota, insulin resistance, obesity, and inflammatory
reactions
Insulin resistance and obesity have been linked to the rise in the rate of infiltration
of inflammation and macrophages in the adipose tissue [105, 106]. As gut microbiota is
reported to be a significant contributor of increasing the prevalence of the obese
phenotype, mostly in mice as it has been confirmed by several researchers, it is also
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deemed to contribute to a high level of adipose inflammation [107, 108]. This type of
model where adipose inflammation is independent of diet but dependent on microbiota
can be evidenced by the finding resulting from a study conducted using C57Bl6 common
laboratory mice. The study reported that the mice exhibited minimized adiposity as well
as lower levels of endotoxins in the blood when fed with diets that have been inducted
with adiposity. Moreover, the mice demonstrate enhanced level of glucose metabolism
and a reduced level of macrophage infiltration in the white adipose tissue. The occurrence
of obesity in mice is also reported to be linked to the increase in the amount of mast cells,
T cells as well as the reduction in the amount of regulatory T cells [38, 109]. When using
the mouse models, there is an indication of generation of short-chain acids and
fermentation of fiber, which demonstrates the promotion of anti-inflammatory reactions
both through regulatory T cells systematically and within the gut [35, 110]. While
interleukin (IL)-17 (an inflammatory cytokine) is involved in the pathogenesis of diabetes
and obesity [111, 112]. There is no doubt that the dietary fiber and the short-chain acids
produced in the model mice result in a positive metabolic effect through nonimmunological strategies [113]. The mouse used for the study are those that had been
obesity-induced. However, it is not clear whether the same outcome that would result
from the immune system could lead to metabolic alterations. While the processes that
underlie these procedures remain unclear, research suggests that when high fat diets are
supplements with fermented fiber, the mice are protected from suffering from obesity and
its associated diseases and disorders.
It is widely acknowledged that diet, especially fiber and processed foods have a
great influence on gut microbiota and consequently on type 2 diabetes and obesity. As
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obesity is significantly correlated to the development of low grade chronic inflammation,
diabetes and obesity are common resultant health complications due to the contribution of
the inflammation on the risk of insulin resistance and body weight. Moreover, individuals
risk suffering from other health problem related to obesity including cardiovascular
diseases [105]. Obesity is also attributed to modified gut microbiota. This is illustrated by
the metabolism of indigestible polysaccharides in a process that produces
monosaccharides and short chain acids that allow for such products to be absorbed and
stored in the body as fat. The general body of research tying diet to gut microbiota and
health outcomes demonstrates that diet low in fiber interacts to effect alternation of the
inflammation in the intestines, a move that is followed by other health complications such
as insulin resistance, adiposity, and weight gain, hence predisposing individuals to type 2
diabetes and obesity.
1.1.11 Dairy products for probiotic benefits
Manipulation of the gut microbiota through dietary intervention and probiotic
supplements is a promising strategy for the prevention and treatment of metabolic
diseases. As a consequence, worldwide sales of probiotics have more than doubled in the
last decade alone [114]. On the other hand, probiotic bacteria have often been assessed as
dietary supplements or in dairy products, such as yogurt or kefir [115, 116]. Because of
its nutritional values and longer shelf life, fermented cheese might be an ideal vector for
the delivery of probiotics. Cheese is a good matrix for transferring probiotic bacteria into
the gastrointestinal tract, due to the buffering capacity of the milk proteins which will
protect the cells during transit; this is mainly due to their higher fat content and denser
structure that may protect the bacteria against the acidic environment of the
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gastrointestinal tract [117-119]. While several studies have shown an inverse association
between dairy products and metabolic syndrome [120-122], however, it is not clear
whether the same outcome that would result from the different sources of (cow, goat and
camel) and formats (milk, yogurt, probiotic yogurt, cheese and probiotic cheese) could
lead to gut microbiota alterations. While the processes that underlie these procedures
remain unclear, research suggests that when full-fat dairy are supplements with specified
probiotic, the mice are protected from suffering from obesity and its associated diseases
and disorders.
1.1.12 Links between diet, antibiotics treatment, gut microbiota, and immunological
status
Linking diet to the structure and dynamic operation of microbial communities
and, more importantly, to the immunological status of the host has proven elusive
because of numerous uncontrolled genetic and environmental variables and the
intrinsically complicated nature of clinical trials. In the past, germ-free mice (animals
born and raise without any exposure to micro-organisms) have provide an excellent
system for controlling host genotype, diet and environmental conditions. In addition, they
can be colonized at specific life stages with different microbial communities and thus
perform comparative metagenomic studies of donor communities [123, 124]. However,
raising and maintaining a germ-free mice colony is challenging. Hence, a broad range
antibiotic treatment of mice is considered a viable alternative and has been successfully
used in the past. Antibiotics have been administered by either oral or intraperitoneal route
[125-127]. However, several studies have shown a negative repercussions between
antibiotic treatment and composition of gut microbiota, including dysbiosis as well as
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metabolic functions and immune responses [128, 129]. While the processes that underlie
these procedures remain unclear, research suggests that when diet are supplements with
specified probiotic and prebiotic, the mice are protected from suffering from this
repercussions as well as attenuating antibiotic-induced disturbances in the gut microbiota
composition.
1.1.13 Summary
This review explores a wide scope of literature on the effects of diet on gut
microbiota and health outcomes including obesity and metabolic disorders taking into
perspective diets such as high fat, whole grains, dairy products, prebiotic and probiotic.
High fiber diet as well as diet rich in prebiotic and probiotic is deemed to be effective in
mitigating the occurrence of diabetes and obesity as they enhance metabolism and
digestion, minimizing the risk of bowel obstruction. Recent human and animal studies
suggest that such intervention can promote health benefits by influencing the aspects of
metabolism and immunity. However, study of the multi-role association between the diet,
host and the microbiota remains to be clarified. My dissertation attempts to clarify the
problem of how gut microbiota (taxonomic composition and predicted functional
capacities) affects obesity and metabolic disorders, and provided important information
on correcting disruption of the gut microbiota resulting from obesity or imbalanced diets
using a combine probiotic and prebiotic (synbiotics), and dairy products which can be
effectively employed for the delivery of probiotics to the gut as well as for the support of
growth and survival of probiotic bacteria.
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Abstract: Targeting gut microbiota with synbiotics (probiotic supplements
containing prebiotic components) is emerging as a promising intervention in the
comprehensive nutritional approach to reducing obesity. Weight loss resulting from lowcarbohydrate, high-protein diets can be significant, but has also been linked to potentially
negative health effects due to increased bacterial fermentation of undigested protein
within the colon and subsequent changes in gut microbiota composition. Correcting
obesity-induced disruption of gut microbiota with synbiotics can be more effective than
supplementation with probiotics alone because prebiotic components of synbiotics
support growth and survival of probiotic bacteria. The purpose of this placebo-controlled
intervention clinical trial was to evaluate effects of a synbiotic supplement on
composition, richness and diversity of gut microbiota and associations of microbial
species with body composition parameters and biomarkers of obesity in human subjects
participating in a weight loss program. The probiotic component of the synbiotic used in
the study contained Lactobacillus acidophilus, Bifidobacterium lactis, B. longum, and B.
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bifidum and the prebiotic component was a galactooligosaccharide mixture. The results
obtained indicated that there were no statistically significant differences in body
composition (body mass, BMI, body fat mass, body fat percentage, body lean mass, and
bone mineral content) between the placebo and synbiotic groups at the end of the clinical
trial (3-month intervention, 20 human subjects participating in weight loss intervention
based on a low-carbohydrate, high-protein, reduced energy diet). Synbiotic
supplementation increased abundance of gut bacteria associated with positive health
effects, especially Bifidobacterium and Lactobacillus, and it also appeared to increase the
gut microbiota richness. A decreasing trend in the gut microbiota diversity in the placebo
and synbiotic groups was observed at the end of trial, which may imply the effect of the
high-protein, low-carbohydrate diet used in the weight loss program. Regression analysis
performed to correlate abundance of species containing in the synbiotic supplement with
body composition parameters and biomarkers of obesity found association between a
decrease over time in blood glucose and an increase in Lactobacillus abundance,
particularly in the synbiotic group. However, the decrease over time in body mass, BMI,
waist circumstance, and body fat mass was associated with a decrease in Bifidobacterium
abundance. The results obtained support the conclusion that synbiotic supplement used in
this clinical trial modulates human gut microbiota by increasing abundance of potentially
beneficial microbial species and that the supplement may have positive effects on
metabolic parameters in obesity.

Keywords: synbiotic; prebiotic; probiotic; gut microbiota; obesity; weight loss; body
composition; obesity biomarkers
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2.1. Introduction
The gut microbiota appears to play a role in the pathogenesis of obesity and
obesity-associated diseases [130, 131]. This community can contribute to the
development of obesity primarily by influencing dietary energy intake and intestinal
absorption of nutrients [132, 133], but it can also provide the human host with benefits
besides energy extraction, including a reduction of low grade chronic inflammation
associated with obesity and metabolic syndrome [134, 135]. Therefore, gut microbiota
may be considered as a promising target in the comprehensive dietary approach to the
prevention and treatment of obesity, including weight loss and weight maintenance [136,
137].
It is important to note that high-protein and low-carbohydrate diets, which are
often successfully used for weight loss, have been associated with a decrease in bacteria
considered beneficial to health [47, 138, 139]. Those diets have also been found to induce
protein fermentation by gut microbiota with formation of metabolic byproducts [140142], which can trigger inflammation in the colon [143]. Furthermore, high levels of
protein fermentation by gut bacteria have been associated with increased genotoxicity
[144]. Thus, a healthy, diverse, and less toxic gut microbiota is critical for wellbeing of
the host [145, 146].
Dietary intervention with probiotics, prebiotics or synbiotics (which combine
probiotic and prebiotic components) aimed at correcting disruption of the gut microbiota
resulting from obesity or imbalanced diets may provide health benefits by facilitating
weight loss and maintenance [147, 148]. Recent human and animal studies suggest that
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probiotics can promote weight loss in obesity [149, 150], but studies on the role of
synbiotics in obesity are very limited [151, 152] and further studies are warranted [151].
The objective of this placebo-controlled intervention clinical trial was to evaluate
effects of a synbiotic supplement containing Bifidobacterium and Lactobacillus strains on
the human gut microbiota in relation to changes in body composition and metabolic
biomarkers in obesity. The results obtained and bioinformatic analysis support the
conclusion that the synbiotic supplement used in this study modulates the human gut
microbiota by increasing abundance of beneficial microbial genera and that the
supplement may also have beneficial effects on metabolic parameters in obesity.

2.2. Materials and Methods
2.2.1. Study Participants, Clinical Trial Design and Prebiotic Supplement
Participants of the study were enrolled in the weight loss program (Profile by
Sanford Health, Sioux Falls, SD). Twenty new weight loss participants, male and female,
were recruited for the study and randomly assigned to the placebo (control) or synbiotic
(treatment) group. Those enrolled were initially overweight/obese and had a mean BMI
of 33.5 kg/m2. Placebo group (n=10) followed the weight loss program eating plan (a
low-carbohydrate, high-protein dietary pattern with reduced energy (4,000-5,000 kJ/d)
intake). The synbiotic group (n=10) was on the same diet plan, but additionally received a
synbiotic (probiotic plus prebiotic) supplement daily for 3 months. The control group
received the placebo supplement similar in appearance and of the same energy content as
the synbiotic supplement. Human subjects with conditions that may impact gut
microbiota (gastrointestinal, autoimmune, and metabolic diseases and medications,
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particularly antibiotics) were not included in the trial. All subjects gave their informed
consent for participating in the study. The study was approved by the SDSU Institutional
Research Board (Approval number: IRB-1604005). The clinical trial has been registered
in the ClinicalTrials.gov (NCT number: 03123510).
The probiotic component of the synbiotic used in the study contained a blend (one
capsule contained 69 mg or 15x109 CFU) of proprietary strains of Lactobacillus
acidophilus DDS-1, Bifidobacterium lactis UABla-12, B. longum UABl-14, and B.
bifidum UABb-10. The probiotic supplement was produced by UAS Labs (Wausau, WI).
The prebiotic component was a trans-galactooligosaccharide (GOS) mixture at a dose of
5.5 g/d (2.75 g GOS and the remainder simple sugars) produced by Clasado BioSciences
Ltd. (St. Helier, Jersey, UK) [153].
2.2.2. Body Composition and Metabolic Parameters
Body mass index (BMI) was calculated using body weight and height measured
with bare feet and in minimal clothing using a stadiometer and an electronic scale. Body
composition parameters (body fat mass and percentage, body lean mass, and bone
mineral content) were acquired before and after 3 months of synbiotic intervention by
dual-energy X-ray absorptiometry (DXA) using a whole-body scanner (Hologic APEX,
Bedford, MA)[154]. Whole-body images were obtained and analyzed by a technologist
certified as a Certified Bone Densitometry Technologist by the International Society of
Clinical Densitometry. Phantom scans were performed before participant testing as an
independent assessment of system calibration, and quality control data were plotted and
reviewed periodically. The A1CNow+ test (MDSS GmbH, Germany/Polymer
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Technology Systems, Inc., USA) was used for quantitative measurement of the percent of
glycated hemoglobin (%A1C) in the capillary blood (fingerstick) samples.
2.2.3. Microbial DNA Extraction and the 16S rRNA Gene Sequencing
Fecal samples from the participants were obtained before and after the synbiotic
or placebo intervention with no more than 24 h prior to the study visit. Samples were
collected using the OMNIgene-GUT stool/feces collection kit (OMR-200, DNA Genotek,
Ottawa, Canada). Forty fecal specimens from unique participants were sent to DNA
Genotek for the microbiome analysis. DNA was extracted and quantified and library
preparation was performed with Illumina’s NexteraXT protocol. Aliquots of each sample
were extracted using PowerMag microbial DNA isolation kit (MO BIO Laboratories,
Carslbad, CA) optimized for the KingFisher Flex automated extraction platform
(ThermoFisher, Pittsburgh, PA). A bead-beating step with glass beads was used to
maximize recovery of DNA from low-abundance and difficult to lyse microorganisms.
The concentration of extracted DNA was measured using Qubit Fluorometer (Invitrogen,
Carslbad, CA), and the sample purity was confirmed spectrophotometrically by
measuring the A260/A280 ratio.
For DNA sequencing, Illumina sequencing adapters and dual-index barcodes
(Nextera XT indices) were added to the amplicon target via polymerase chain reaction
(PCR) amplification. 16S sequencing (2x300 bp PE V3-V4) was performed on Illumina’s
MiSeq platform. Amplicon sequencing was performed to a target depth of 30,000 reads
per sample. Paired-end reads from each sample were merged, screened for length and
filtered for quality using DNA Genotek’s proprietary 16S pre-processing workflow. Read
merging and quality filtering was performed on the raw sequencing reads to eliminate
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any sequencing artifacts and low quality reads. Complete quality metrics including
library quantification and sequencing run quality control are presented in Supplemental
Materials (Figure 2-S1 and Table 2-S1).

Figure 2-S1. Sequence counts per sample for raw, filtered and classified sequences
ordered by increasing classified sequence counts. Dashed gold line indicates the 25,000
sequence threshold used for rarefaction. A and B before sample numbers indicate the
synbiotic and placebo groups, respectively.

Metric

Minimum Requirement

Results

% ≥ Q30

≥ 75%

82.38 %

Cluster Density

≥ 800 k/mm2

1,111 ± 19 k/mm2

Clusters Passing Filter (%)

≥ 85%

86.49 ± 1.34 %

Sequencing Yield

≥ 13.2 Gbp

14.04 Gbp

PhiX Alignment (%)

12% - 18%

11.63 %

32

Table 2-S1. Sequence quality metrics per sequencing run. % ≥ Q30: The proportion of
base calls that have a confidence score of 30 or more. This is a commonly cited metric
that can be used to evaluate the overall quality of a sequencing run. Cluster Density: How
efficiently the sequencer is able to bind sequences of DNA to the flow cell. A higher
density represents a more efficient sequencing run. Clusters Passing Filter: The
proportion of clusters that meet the sequencer’s minimum quality threshold for sequence
quality. Only clusters that pass filter are included in the sequencer’s FASTQ output.
Sequencing Yield: Refers to how many nucleotide base pairs were called by the
sequencer. 1 Gbp (giga base pair) means the sequencer generated 1 billion base pairs of
output. PhiX Alignment: PhiX is a sequencing library that is used as a positive control on
each sequencing run. The sequencer aligns reads to the PhiX library to calculate
sequence-based quality control metrics. We require that the percentage of reads that align
to the PhiX library is within 20% of the spike-in amount of PhiX.

2.2.4. Taxonomic Classification and Bioinformatics Analysis
A curated reference taxonomic database was used to assign a taxonomic
classification to the sequencing reads. High quality sequences were aligned to the curated
reference database at 97% similarity using the NINJA-OPS algorithm, version 1.5.1
[155]. At 97% sequence identity, each operational taxonomic unit (OTU) represents a
genetically unique group of biological organisms. These OTUs were then assigned a
curated taxonomic label based on the SILVA taxonomic database, version 123 [156]. The
relative abundance of all taxa at the phylum and genus levels were plotted to visualize
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sample-specific classifications. All samples were rarefied to an even depth of 25,000
classified sequences per sample or more to eliminate effects of variance in sequencing
depth. Samples with more than 25,000 classified sequences per sample were included in
the rarefied OTU table and downstream analyses, thus allowing to rarefy the samples to
52,150 read pairs/sample, as this was the read count of the sample with the fewest reads
(see Table 2-S1).
Alpha diversity metrics (observed OTUs, Shannon index, and Chao1 diversity)
were calculated on the rarefied OTU table using the alpha_rarefaction.py workflow in
QIIME 1.9.1 [157]. Beta diversity metrics (weighted and unweighted UniFrac distances)
were calculated on the rarefied OTU table with the beta_diversity.py workflow in QIIME
1.9.1 and Bray-Curtis dissimilarity index was calculated on the species level
summarization of the rarefied OTU table. Differences between groups were estimated
using Permutational Multivariate Analysis of Variance (PerMANOVA; adonis function
in the vegan R package). Principal Coordinates Analysis (PCoA) was applied to each beta
diversity distance matrix using the dudi.pco function from the R package made4 (version
1.48.0). The first two major axes were plotted (R package ggplot2 version 2.2.1), and the
percentage of variance explained by each axis was indicated.
2.2.5. Statistical analysis
A one-way ANOVA with independent samples t-test was used for group
comparison of the body composition and metabolic parameters (SPSS Statistics, v. 25).
The results were expressed as mean ± SD, and mean differences were considered
significant at p < 0.05. Significant differences in alpha diversity between groups were
determined using estimated marginal means analysis applied to linear mixed model,
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which was built with alpha diversity as the response variable, the treatment groups and
time points as the predictor variables, and subject number as a random variable.
Significant differences in beta diversity between groups were determined using
PerMANOVA with beta diversity as the response variable and the treatment groups and
time points as predictor variables. Statistical analyses of diversity metrics were performed
using R version 3.3.2 (R Core Team, 2015).
Associations between relative abundance of gut bacteria and the body
composition and metabolic parameters were calculated using Pearson’s linear correlation
coefficient. Regression analysis to correlate microbial abundance of species/genera
present in the synbiotic supplement (Bifidobacterium and Lactobacillus) with body
composition parameters and biomarkers of obesity was performed by applying ANOVA
to a mixed linear model build with the percent abundance of microbe of interest as the
response variable and the interaction between the specific parameter (gender, age, body
mass, weight circumstance, BMI, body fat mass, body fat percentage, lean mass, bone
mineral content, or HbA1C), treatment groups (placebo or synbiotic) and time points
(beginning or end of trial) as predictor variables, with subject number as random variable.
The Bonferroni correction method was used for multiple testing. Software versions used
for the data analyses are provided in supplemental Table 2-S2.
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Software

Version

Trimmomatic

0.36

NINJA-OPS

1.5.1

SILVA taxonomic database 123
QIIME

1.9.1

SPSS Statistics

25

R

3.3.2

R packages
emmeans

1.2

lme4

1.1-17

Matrix

1.2-14

scales

0.5.0

ggplot2

2.2.1

reshape2

1.4.3

made4

1.48.0

scatterplot3d

0.3-41

gplots

3.0.1

RColorBrewer

1.1-2

ade4

1.7-11

vegan

2.5-1

lattice

0.20-35

permute

0.9-4

Table 2-S2. Software versions for data analysis.
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2.3. Results
In this placebo-controlled intervention clinical trial, effects of the synbiotic
supplement on richness and diversity of gut microbiota and associations of microbial
species with measurements of body composition and biomarkers of obesity were
evaluated in human subjects participating in a weight loss program. Twenty participants
were recruited in the study (10 in the placebo (control) group and 10 in the synbiotic
(treatment) group). The average BMI of the study participants was 33.5 kg/m2 and the
average age was 47.4 years. The majority of participants were female (80% in the
placebo group and 70% in the synbiotic group).
Participants were enrolled in the weight loss program at the beginning of the
study and followed a low-carbohydrate, high-protein, reduced-energy intake eating plan.
The probiotic component of the synbiotic used in the study contained Bifidobacterium
spp. and Lactobacillus acidophilus strains, and the prebiotic component stimulating
growth of these bacteria was a trans-galactooligosaccharide mixture. Blood and fecal
samples were collected and body composition and metabolic parameters measured at the
beginning and end of the three-month intervention trial. Seven human subjects in the
placebo group and eight human subjects in the synbiotic group had body composition
parameters measured using DXA. No participants dropped out of the study during the
intervention period.
2.3.1. Body Composition and Metabolic Parameters
The results obtained indicate that there were no statistically significant differences
in the body composition parameters (body mass, waist circumstance, BMI, body fat mass,
body fat percentage, body lean mass, bone mineral content (as measured by DXA) and
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obesity-related biomarkers (blood glucose, as measured by HbA1C levels) between the
placebo and synbiotic groups at the end of the clinical trial (three-month synbiotic
intervention) (Table 2-1). Body mass, waist circumference, BMI, fat mass, fat
percentage, and glucose level significantly decreased or demonstrated a decreasing trend
in the placebo and synbiotic groups at the end of the trial (participants in both the placebo
and synbiotic groups were enrolled in the weight loss program). The decrease in HbA1C
percentage at the end of trial was statistically significant in the synbiotic group, but not in
the placebo group. Individual body composition parameters, including the DXA scan
measurements, are presented in appendix Table 2-S3.
Characteristics/Parameters
Sex (%)
Male
Female
Age (years)
Height (cm)
Body mass (kg)
Baseline
End of trial
Body mass change (%)
BMI (kg/m2)
Baseline
End of trial
BMI change (%)
WC (cm)
Baseline
End of trial
WC change (%)
Body Fat Mass (kg)
Baseline
End of trial
Fat mass change (%)
Body Fat (%)
Baseline

Placebo

Synbiotic

p

20.0
80.0
47.0 ± 15.4
171.8 ± 12.9

30.0
70.0
47.8 ± 8.99
163.4 ± 9.63

0.88
0.30

97.6 ± 23.1
90.0 ± 21.9
7.78 ± 5.30*

90.6 ± 11.9
83.4 ± 11.4
7.94 ± 3.88*

0.40
0.41
0.86

32.77 ± 4.51
30.14 ± 4.04
8.02 ± 1.65*

34.20 ± 5.60
31.48 ± 5.23
7.95 ± 1.52*

0.53
0.53
0.82

106.9 ± 12.47
101.1 ± 12.89
5.42 ± 5.78*

109.6 ± 8.07
102.6 ± 8.48
6.38 ± 4.16*

0.57
0.76
0.29

40.66 ± 6.92
37.44 ± 6.99
7.91 ± 2.73*

36.97 ± 11.35
34.06 ± 11.58
7.87 ± 3.94*

0.47
0.51
0.37

40.97 ± 5.02

40.51 ± 8.96

0.90
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End of trial
Body fat change (%)
Body Lean Mass (kg)
Baseline
End of trial
Lean mass change (%)
BMC (kg)
Baseline
End of trial
BMC change (%)
Body Lean Mass + BMC(kg)
Baseline
End of trial
Lean mass +BMC change (%)
HbA1C (%)
Baseline

39.51 ± 4.53
3.56 ± 1.49*

39.13 ± 9.47
3.40 ± 2.97

0.92
0.20

57.39 ± 17.76
55.61 ± 16.15
3.10 ± 2.10*

51.13 ± 8.87
49.47 ± 8.64
3.24 ± 1.14*

0.39
0.36
0.25

2.66 ± 0.64
2.68 ± 0.67
0.75 ± 0.05

2.38 ± 0.48
2.38 ± 0.48
0.16 ± 0.01

0.34
0.32
0.10

60.05 ± 18.38
58.30 ± 16.78
2.91 ± 2.08*

53.52 ± 9.35
51.86 ± 9.11
3.10 ± 1.13*

0.39
0.36
0.26

5.36 ± 1.07

5.39 ± 0.28

0.93

End of trial
HbA1c change (%)

5.06 ± 0.37
5.59 ± 0.89

5.06 ± 0.43
6.12 ± 0.47*

1.00
0.24

Table 2-1. Characteristics of study participants at the beginning and end of the
intervention clinical trial. BMI, Body Mass Index; WC, Waist Circumference; BMC,
Bone Mineral Content; HbA1C, glycated hemoglobin. The duration of the trial was 3
months. The study enrollment period was 6 months, and subjects were assigned to the
groups in a chronological order. n = 10 for the placebo group and n = 10 for the synbiotic
group (7 human subjects in the placebo group and 8 human subjects in the synbiotic
group completed DXA scans). The results are expressed as mean ± SD. A one-way
ANOVA with independent t-test was used for the group comparison (SPSS Statistics, v.
25). (*), p < 0.05, as compared between the beginning (baseline) and end of trail for the
same group (placebo or synbiotic); p value, as compared between the placebo and
synbiotic groups.
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The findings obtained demonstrate that the low-carbohydrate, high-protein,
decreased-energy diet is effective for weight loss and normalizing obesity-related
metabolic parameters (blood glucose), but they do not support the conclusion that the
synbiotic supplement used in the study has significant impact on body mass and body
composition of human subjects participating in this weight loss program.
2.3.2. Gut Microbiota
To characterize effects of the synbiotic supplement on gut microbiota of the study
participants, fecal samples were obtained before and after the synbiotic intervention, gene
sequence analysis was performed, and individual variations as well as group differences
of gut microbiota were compared. All samples underwent taxonomic classification and
were included in the complete OTU table (supplemental Table 2-S4), however, those
with fewer than 25,000 classified sequences per sample were excluded from further
analysis. Remaining samples were rarefied to a depth of 52,150 sequence reads per
sample. Raw read counts per sample, quality of filtered read counts per sample, and
sequence quality metrics per sequencing run are provided in Supplemental Materials (see
Figure 2-S1 and Table 2-S1). The relative abundance of all taxa at the phylum, genus,
and species levels were plotted to visualize broad taxonomic differences by treatment
groups and time points with a percentage of each number in all sequencing reads (Figure
2-1 and Figure 2-S2). In addition, the relative abundance of phyla, genera, and species
per sample were plotted (supplemental Figure 2-S3).
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Figure 2-S3. Relative abundance of phyla (S3A), genera (S3B) and species (S3C) per
individual sample. A and B before sample numbers indicate the synbiotic and placebo
groups, respectively.

The data obtained confirmed that Firmicutes and Bacteroidetes were the two most
abundant bacterial phyla in the gut (see Figure 2-1A) and Bacteroides was the most
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abundant genus (see Figure 2-1B). The synbiotic supplementation induced statistically
significant alterations in the composition of the gut microbiota at the end of trial, as
compared with the placebo group (Figure 2-2). All data were remained significant after
adjusting for multiple testing (supplemental Table 2-S5). At the phylum level, increases
in relative abundance of Cyanobacteria, Euryarchaeota, Fusobacteria, and
Lentisphaerae were observed following synbiotic intervention. At the genus level,
relative abundance of Ruminococcus, Bifidobacterium, Sutterella, Tyzzerella,
Eisenbergiella, Eubacterium, Eggerthella, Methanobrevibacter, Lachnospiraceae,
Edwardsiella, Lactobacillus, Allobaculum, Enterococcus, Hydrogenoanaerobacterium,
Coprococcus, and Butyricimonas were significantly higher. The relative abundance of
Ruminococcaceae, Prevotella, Gardnerella, Turicibacter, and Megasphaera at the end of
trial was significantly lower in the synbiotic group, as compared with the placebo group.
These results indicate that the synbiotic supplement used in the study modified relative
abundance of gut bacteria, some of which can be associated with health benefits
(particularly, significantly increased abundance of Bifidobacterium and Lactobacillus).
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Figure 2-1. Mean relative abundance (%) of phyla (A) and genera (B) by the treatment
groups and time points.
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Figure 2-2. Changes in the relative microbial abundance in the gut after synbiotic
intervention. *p < 0.05, **p < 0.01, ***p < 0.001, as compared with the placebo group at the
end of trial.
Gut microbiota

p-value

Megasphaera

0.003

Prevotella 2

0.001

Turicibacter

0.004

Gardnerella

0.0001

Prevotella 9

0.001

Ruminococcaceae UCG-011

0.019

Butyricimonas

0.0001

Coprococcus 2

0.007

Hydrogenoanaerobacterium

0.018

Enterococcus

0.001

Allobaculum

0.002

Eubacterium ruminantium group

0.008

Lactobacillus

0.041

Edwardsiella

0.001

Lachnospiraceae ND3007 group

0.012

Methanobrevibacter

0.015

Eggerthella

0.001

Eubacterium oxidoreducens group

0.011

Eisenbergiella

0.009

Tyzzerella 4

0.005

Sutterella

0.013

Bifidobacterium

0.004

Ruminococcus 2

0.003
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Ruminococcus 1

0.002

Lentisphaerae

0.037

Fusobacteria

0.037

Euryarchaeota

0.022

Cyanobacteria

0.047

Table 2-S5. Bonferroni adjusted P-values. The Bonferroni correction sets the
significance cut-off at α/n. With 28 tests (gut microbiota, n=28) and (α= 0.05), we'd only
reject a null hypothesis if the p-value is less than 0.0017.

Alpha diversity metrics were used to measure species richness and evenness
(similar abundance) in the groups (Figure 2-3 and Table 2-2). The number of OTUs, the
Chao1 estimator (a measure of community richness), and the Shannon Index (a measure
of richness and evenness or entropy) were calculated. Data analysis showed that there
were no significant differences in alpha diversity metrics between treatment groups and
time points (Figure 2-3B). Shannon index pointed to a decreasing trend in microbial
diversity at the end of trial in both the placebo and synbiotic groups (Figure 2-3C). This
data suggests that the observed decrease in microbial diversity in the placebo and
synbiotic groups at the end of trial implies involvement of other factors, probably, the
effect of the high-protein, low-carbohydrate, energy-restricted diet used in this weight
loss program.
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Figure 2-3. Observed species (A), Chao1 diversity (B) and Shannon diversity (C) plotted
by the treatment group and time point. The box spans the first and third quartiles. A
horizontal line marks the median and the whiskers represent ±1.5-times the interquartile
range. Outliers (panels A and B) are marked as individual points. Significant differences
between groups were determined using the estimated marginal means analysis applied to
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linear mixed model, which was built with alpha diversity as the response variable, the
treatment group and time points as predictor variables, and subject number as a random
variable.
Groups

Shannon Index

Chao1 Diversity

Observed Species

Within

Between

Estimate p-value Estimate p-value Estimate p-value

Baseline

Placebo - Synbiotic

0.144

0.643

295.0

0.359

222.0

0.388

End of Trial Placebo - Synbiotic

0.145

0.641

205.4

0.521

180.9

0.481

Placebo

Baseline - End of Trial 0.208

0.208

76.94

0.577

76.20

0.460

Synbiotic

Baseline - End of Trial 0.209

0.206

-12.65

0.927

35.10

0.732

Table 2-2. Measuring statistically differences in alpha diversity between groups. Three
alpha diversity metrics were used (Shannon Index, Chao1 Estimator, and Observed
Species/OTUs). Significant differences between groups were determined using the
estimated marginal means analysis applied to linear mixed model, which was built with
alpha diversity as the response variable, the treatment group and time points as predictor
variables, and subject number as a random variable.

Beta diversity metrics were used to compare differences in the community
composition of two different samples. Bray-Curtis dissimilarity was used to compare the
abundance of each OTU between two samples to give a metric between 0 and 1;
weighted UniFrac distance, which is a dissimilarity metric that uses the phylogenetic
distribution of the OTUs in a sample together with the abundance of those OTUs to

48

measure the distance between two samples; and unweighted UniFrac distance, which also
measures the phylogenetic distribution of the OTUs in a sample, but relies only on
presence/absence data instead of abundance data [158]. An assessment of the distances
within and between time points and groups did not reveal significant changes in the
community structure (Table 2-3).

Groups

Bray-Curtis
Dissimilarity

Weighted UniFrac

Unweighted
UniFrac

Within

Between

F-model

p-value

F-model

p-value

F-model

p-value

Baseline

Placebo - Synbiotic

1.393

0.133

0.840

0.516

1.155

0.232

End of Trial

Placebo - Synbiotic

1.389

0.158

0.923

0.379

1.038

0.325

Placebo

Baseline - End of
Trial

0.376

0.996

0.389

0.932

0.351

1.000

Synbiotic

Baseline - End of
trial

0.431

0.983

0.305

0.958

0.392

1.000

Table 2-3. Measuring statistical significant of beta diversity differences between groups
using Permutational Multivariate Analysis of Variance (PerMANOVA) on models with
beta diversity as the response variable, and treatment group and time point as predictive
variables. Three beta diversity metrics were used (Bray-Curtis, weighted UniFrac, and
unweighted UniFrac).
To visually identify whether groups of samples cluster based on similarity to each
other, PCoA plots were generated to highlight separation of groups of samples for
unweighted UniFrac distance, weighted UniFrac distance, and Bray-Curtis dissimilarity
distance (Figure 2-4). No statistically significant differences in microbial diversity
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between or within the placebo and synbiotic group at the baseline and end of trial were
observed.

Figure 2-4. Principal Coordinates Analysis (PCoA) of unweighted UniFrac (A), weighted
UniFrac (B) and Bray-Curtis dissimilarity data (C). Scatter plots show principal
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coordinate 1 (PC1) vs. principal coordinate 2 (PC2) with percentages of variation
explained by the components indicated. Points are colored by the treatment group and
time point.
2.3.3. Associations between gut microbiota, body composition and metabolic
parametersIn order to explore associations between the gut microbial species and body
composition and metabolic parameters, regression and correlation analyses were
performed as described in the Methods section. Regression analysis to correlate relative
microbial abundance of species present in the synbiotic supplement with body
composition parameters and biomarkers of obesity found association between a decrease
over time in blood glucose and an increase in Lactobacillus abundance in the synbiotic
and placebo groups. In both groups combined, a mean decrease in HbA1C% (5.85%, see
Table 1) was accompanied by a mean increase in Lactobacillus abundance (24.1-fold, see
Fig. 2; p = 0.044). However (and somewhat paradoxically), a decrease over time in body
mass, BMI, waist circumstance, and body fat mass was associated with a statistically
significant decrease in Bifidobacterium abundance in both the placebo and synbiotic
groups (Table 2-4).
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Parameters

Change

Gut microbiota

Change

P

HbA1C%

↓ 5.85%

Lactobacillus

↑ 24.1- fold

0.044

Body mass (kg)

↓ 7.86%

Bifidobacterium

↓ 263.8- fold

0.052

BMI (kg/m2)

↓ 7.98%

Bifidobacterium

↓ 263.8- fold

0.009

WC (cm)

↓ 5.90%

Bifidobacterium

↓ 263.8- fold

0.023

Body Fat Mass (kg)

↓ 7.89%

Bifidobacterium

↓ 263.8- fold

0.011

Table 2-4. Association between changes over time in (body composition and metabolic
parameters) and changes in gut microbiota abundance in the synbiotic and placebo groups
(both groups combined). BMI, Body Mass Index; WC, Waist Circumference; HbA1C,
glycated hemoglobin. Data was generated by applying analysis of variance to a mixed
linear model, built with the abundance of a given microbe as the response variable, and
body composition, metabolic parameter, treatment groups and time points as the predictor
variables, with subject number as random variable.
The Pearson’s linear correlation test (Figure 2-5) did not indicate statistically
significant associations between Bifidobacterium and Lactobacillus abundance and body
composition parameters in the synbiotic group at the end of trial. A negatively correlated
trend was observed between Bifidobacterium abundance and HbA1C levels in the
synbiotic and placebo groups, whereas a positively correlated trend between
Bifidobacterium abundance and, to a lesser extent, Lactobacillus abundance was
observed with BMI, WC, and body fat mass in the synbiotic group. Interestingly, in the
placebo group, Lactobacillus abundance was negatively correlated with body fat mass.
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Cyanobacteria, Sutterella, Butyricimonas, and Eubacterium ruminantium
abundance (which were increased following the synbiotic intervention) were significantly
negatively correlated with body fat mass, and Cyanobacteria and Sutterella abundance
was negatively correlated with body fat percentage. Additionally, Butyricimonas
abundance positively correlated with BMC. Eubacterium abundance positively correlated
with HbA1C percentage, whereas Megasphaera abundance (which was decreased after
the synbiotic intervention) was negatively correlated with this marker. Positive
correlations were found between Coprococcus abundance and body mass, BMI, and WC;
Lachnospiraceae abundance and BMI, WC, and body fat mass; Tyzzerella and
Gardnerella abundance and WC.
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Figure 2-5. Heatmap of associations between gut microbiota, body composition and
metabolic parameters in the placebo (A) and synbiotic groups (B) at the end of trial. r
values were calculated using Pearson’s linear correlation test; *p < 0.05, **p <0.01.
Pearson’s r values below 0.30 or above -0.30 are not indicated. Red-brown color
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indicates negative correlation, blue-green color -- positive correlation.Our data confirmed
several previously reported associations [159-161], however, correlations found for
Lactobacillus and Bifidobacterium were somewhat unexpected, although appear to be
promising for associations with blood glucose levels. The results obtained support the
conclusion that the synbiotic supplement used in this intervention trial modulated the
microbiota by increasing abundance of the microbial genera associated with beneficial
effects. Furthermore, these microbial changes may be associated with positive effects on
metabolic parameters (blood glucose) in obesity.
2.4. Discussion
This study was a placebo-controlled intervention clinical trial designed to
examine the effects of a combination of probiotic bacteria L. acidophilus, B. lactis, B.
longum, B. bifidum and a prebiotic mixture of galactooligosaccharides on the human gut
microbiota in relation to changes in body composition and metabolic biomarkers in obese
human subjects enrolled on a weight loss program. The weight loss program was a highprotein, low-carbohydrate, energy-restricted eating plan. Previous limited studies
conducted using L. acidophilus and B. lactis have found that these probiotic species can
be associated with decreased body weight and body fat percentage [162], while prebiotic
galactooligosaccharides have been shown to improve markers of metabolic syndrome and
modulate the gut microbiota and immune function in overweight adults [153, 163, 164].
However, this study focused on evaluating the effects of synbiotic supplementation in
obesity during weight loss intervention.
The study has confirmed that a high-protein, low-carbohydrate, restricted-energy
diet can be effectively used for weight loss in obese individuals, but it also confirmed that
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such a diet is associated with specific changes in gut microbiota. Previous evidence has
shown that synbiotic supplementation contributes to altering microbial composition,
resulting in benefits to weight loss and maintenance [165]. In the current study
supplementation resulted in microbial changes that have frequently been associated with
benefits to host health. However, how these changes relate to metabolic health remains to
be confirmed. Furthermore, the microbial breakdown of proteins within the large
intestine has been associated with the production of genotoxic and cancer associated
metabolites, e.g. N- nitroso compounds and ammonia [144]. As such, altering the gut
community to one less proteolytic through the introduction of a synbiotic could be of
benefit to the host.
A combination of the four strains of Bifidobacterium and Lactobacillus
acidophilus in the synbiotic supplement resulted in a significant increase in abundance of
these probiotic genera in the gut after a 3-month intervention. Bifidobacterium is largely
considered a positive member of the microbial community and furthermore, there has
been some association with anti-obesity effects [162, 166, 167]. In addition to this,
further modulation of the microbiota was observed, for example, Prevotella and
Gardnerella genera were significantly decreased after the synbiotic intervention (see
Figure 2-2). Previous studies have reported that these genera are associated with chronic
inflammatory conditions and positively correlated with obesity [168-170]. Therefore, the
reduction in these genera could help to modulate the balance to improve metabolism
within the host. Special caution is warranted when analyzing the data referring to
Prevotella, a complex genus linked both to health and disease and maybe influenced by
race/ethnicity [171]. However, statistically significant differences in the community
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composition of gut microbiota between groups (synbiotic vs. placebo) and time points
(end vs. beginning of trial) using parameters of alpha-diversity (see Table 2-2) and betadiversity (see Table 2-3) were not observed. Our data is compatible with a recent study
that did not found a relationship between severe caloric restriction and changes in alphadiversity[172]. In addition, correlation and regression analyses did not indicate
statistically significant or apparently beneficial associations between species contained in
the synbiotic supplement (Bifidobacterium and Lactobacillus) and body composition
parameters, including at the end of synbiotic intervention (see Figure 2-5B). Interestingly,
the changes over time in body mass, BMI, waist circumstance, and body fat mass
demonstrated a positive correlation trend with Bifidobacterium abundance in the
synbiotic group, while changes in body fat mass were negatively correlated with
Lactobacillus abundance in the placebo group. However, positive associations between
relative abundance of Bifidobacterium and several body composition parameters appear
to point to the unfavorable role of these bacteria in promoting weight loss, although any
potential benefits of this genera could be masked by the high-protein diet used in the
study. High protein intake induces proteolytic fermentation in the gut with synthesis of
compounds that have been implicated in the development of obesity and metabolic
syndrome and modulating the gut microbiota [140-142, 173] and the production of toxic
metabolites [174]. Several studies have also found that an increase in Bifidobacterium
and Lactobacillus abundance is correlated with both pro- and anti-obesity effects in obese
human subjects [175, 176], thus complicating the interpretation of the results. Individual
differences in energy extraction may contribute to explain the observed differences [177].
Additionally, Bifidobacterium have been linked with improved barrier function in
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overweight individuals, thus adding a potential beneficial mechanism of action [81].
Therefore, more studies are needed to fully understand the observed divergences and
correctly identify human subpopulations susceptible to benefit from synbiotic
intervention.
Regression analysis performed to correlate microbial abundance of species
contained in the synbiotic supplement with biomarkers of obesity found a novel
significant association between a decrease over time in HbA1C percentage and an
increase in Lactobacillus abundance, particularly in the synbiotic group. This is an
important observation because it demonstrates the beneficial effect of increasing
Lactobacillus abundance on potentially reducing blood glucose levels. Negative
associations between Megasphaera abundance and Eubacterium ruminantium abundance
with HbA1C levels were observed in the synbiotic group at the end of trial. Eubacterium
ruminantium are xylanolytic bacteria (i.e., producing xylanase following dietary fiber
fermentation) and Megasphaera bacteria utilize lactate [178], which can underlie
potential relationship of these species to decreasing blood glucose levels [179, 180].
However, within the trial following the synbiotic a decrease in Megasphera was
observed, an increase in Eubacterium ruminantium. This could imply that the synbiotic
intervention and associated microbial changes could be linked to maintaining a normal
blood glucose levels in obesity.
It should also be considered that the microbial shifts observed in this study may
be associated with a positive impact on microbial fermentation within the large intestine.
Whilst the microbial changes observed following synbiotic intervention included an
increase in Ruminococcus, a genera known to produce butyrate. Butyrate is a short chain
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fatty acid that provides and energy source for the colonocytes, as a histone deacetylase
inhibitor this SCFA is linked to anti-cancer effects, hence could offer protection against
some of the metabolites that are produced within a high protein diet. SCFA’s have also
recently been associated with protection against type 1 diabetes [181]. In addition to this
lactobacilli and bifidobacteria are associated with positive effects of colonic health and
following synbiotic intervention have been associated with reducing fecal water
genotoxicty, which is considered a biomarker for colon cancer [182]. Therefore, whilst
within the weight-loss diet employed the synbiotic treatment may have had a limited
impact on the weight-loss parameters, it is possible that the changes in the microbiota
could help to reduce detriments associated with a high protein diet.
It is important to emphasize that the present study was a randomized, placebocontrolled intervention clinical trial and that analysis of the community composition of
the gut microbiota between the treatment groups and time points was performed using
comprehensive microbiome analysis, including alpha- and beta-diversity metrics and
multivariate analysis of variance. The design of the study has allowed us to detect
important novel associations between composition of the gut microbiota and metabolic
parameters in obesity in the relatively limited number of participants in this clinical trial.
The results obtained and bioinformatic analysis support the conclusion that weight
loss in human subjects participating in a high-protein, low-carbohydrate, energyrestricted eating weight loss program is accompanied by changes in gut microbiota that
can be associated with increased genotoxicity [144]. The synbiotic used in this study
modulated the human gut microbiota by increasing abundance of the microbial species
that can be considered to be of benefit to their host; it was also associated with positive
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effects on metabolic parameters in obesity. Thus, the addition of synbiotic supplements to
weight reduction diets may aid against negative microbial changes associated with high
protein diets and weight loss.
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CHAPTER 3. Effects of probiotic dairy products on gut microbiota and body
weight in mice
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Abstract: Targeting gut microbiota with probiotics has recently emerged as a promising
nutritional approach for the prevention of obesity and metabolic syndrome. Cultured
dairy products can be effectively employed for the delivery of probiotics to the gut as
well as for the support of growth and survival of probiotic bacteria. The purpose of this
study was to characterize the effects of probiotic-enriched pasteurized milks and dairy
products (Greek-style yogurt and cheese) of different origins (cow, goat, and camel) on
the taxonomic composition of the mouse gut microbiota and body weight. Mice were fed
standard low fat, plant polysaccharide-rich (LF/PP) diet supplemented with the probioticenriched dairy products for 5 weeks. Next generation DNA sequencing from mouse fecal
samples was used to obtained data on the bacterial relative abundance. Mice fed a diet
supplemented with camel milk demonstrated a decrease in body weight gain as compared

61

with mice fed LF/PP diet. This was accompanied by characteristic changes in the gut
microbiota, which included an increase in relative abundance of order Clostridiales and
genus Anaerostipes. Mice fed diet supplemented with the probiotic cheese exhibited a
decreasing trend in body weight gain, accompanied by an increase in the relative
abundance of order Clostridiales, family Ruminococcaceae, and family Lachnospiraceae.
The results obtained and their bioinformatics analysis support the conclusion that camel
milk and probiotic cheese induce changes in the mouse gut microbiota, which can be
characterized as potentially health beneficial compared to changes associated with
standard diet or diets supplemented with cow milk, goat milk, and yogurt. These findings
imply that dairy products are effective for the delivery and supporting growth of
probiotics bacteria in the gut and, thus, may contribute to maintaining healthy body
weight.

Keywords: gut microbiota; cultured dairy products; probiotic-enriched dairy products;
body weight

62

3.1. Introduction
Over the last decade an ever growing body of evidence has established the gut
microbiota as one of the most important determinants of metabolic syndrome [183-185].
Importantly, the gut microbiota composition is modulated by several genetic and
environmental factors, including diet among the most important factors [186-188].
Therefore, manipulation of the gut microbiota through dietary intervention and probiotic
supplements can be a promising strategy for the prevention and treatment of metabolic
syndrome and obesity. As a consequence, worldwide sales of probiotics have more than
doubled in the last decade alone [114]. Probiotic bacteria can be delivered to the gut as
dietary supplements or in foods, including dairy products, such as yogurt or kefir [115,
116].
More than 6 billion people worldwide consume milk and dairy products [189].
Milk provides 11 to 14 percent of dietary energy supply in Europe, Oceania and the
Americas [190]. Recent studies have found an inverse relation between consumption of
dairy products and metabolic syndrome and, probably, obesity [191, 192].
We hypothesized that cultured dairy products such as cheese and yogurt can be an
ideal vector for the delivery of probiotics to the gut because of its nutritional value, acidic
nature, and long shelf-life. Cheese is a suitable matrix for transferring probiotic bacteria
into the gastrointestinal tract due to the high buffering capacity of the milk proteins which
can protect the bacterial cells during transit. High fat content and dense structure of
cheese protect bacteria against acidic environment of the gastrointestinal tract [117-119].
While several studies have shown an inverse association between dairy products and
metabolic syndrome and obesity [120-122], studies that comprehensively analyze the
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effects of different milk sources (cow, goat and camel) and products (milk, yogurt,
probiotic yogurt, cheese, and probiotic cheese) on the gut microbiota composition and
body weight are not available.
The objective of this study was to characterize the effect of probiotic-enriched
pasteurized milk, Greek-style yogurt, and cottage cheese made from milk of different
origins (cow, goat, and camel) on the taxonomic composition of the mouse gut
microbiota and body weight. A well-established Clostridium butyricum [193, 194] was
used as probiotic in these studies. The results obtained and their bioinformatics analysis
appear to support the conclusion that camel milk and the probiotic cow cheese induce
changes the mouse gut microbiota, which are associated with the optimal weight gain in
growing mice.

3.2. Materials and Methods
3.2.1. Animals and diets
Female 6-8 weeks old C57BL/6 mice weighing 14-16 g, were purchased from
Jackson Laboratory (Bar Harbor, ME). Upon arrival, they were randomly grouped and
kept in specific pathogen free (SPF) conditions in individually ventilated cages with
sterile bedding at 24-26°C, relative humidity 50 ± 10% and a 12-h light/dark cycle. Mice
were fed ad libitum standard low fat, plant polysaccharide-rich (LF/PP) diet 5001
(LabDiet, St. Louis, MO) supplemented daily with the dairy products for 5 weeks. The
control group was fed standard LF/PP diet without dairy supplementation. Three groups
were supplemented with pasteurized cow milk (DairyPure, Dallas, TX, USA), goat milk
(Meyenberg, Turlock, CA, USA) or camel milk (Desert Farms, Santa Monica, CA). Four
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groups were supplemented with cow yogurt or goat yogurt (with and without probiotics).
Finally, two groups were fed diet supplemented with either a regular cow cheese or a
probiotic cow cheese. There were 5 animals in each experimental group. The amount of
daily supplementations was 1 mL of dairy product per mouse per day. Body weight was
measured weekly using top-loading balances with 0.01 g precision (OHAUS SPX222.,
Pine Brook, NJ). The experiments were approved by the South Dakota State University
Institutional Care and Use Committee (Approval number: 16-024A).

3.2.2. Manufacture of Cultured Dairy Products
The probiotic cheese and probiotic yogurt were manufactured at the Health and
Nutritional Sciences Department facilities utilizing the probiotic strains grown in our
laboratory. The manufacture process for Greek-style yogurt and cottage cheese is
schematized in Figure 3-1, following the procedure described elsewhere [195, 196]. One
liter of yogurt and cottage cheese were produced weekly.
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Figure 3-1. Schematic diagram for the manufacture of cultured dairy products: (a)
Greek-style yogurt and (b) cottage cheese.

3.2.3. Microbial DNA Extraction and the 16S rRNA Gene Sequencing
Fecal samples from mice were obtained at the end of experimental study by
taking individual mice out of their cage and gathering a stool sample in a 2 mL tube. All
fecal samples were immediately frozen at -80°C. DNA was extracted from fecal sample

66

by using the microbial DNA extraction method (ZR Fecal DNA MiniPrep™) as
described by [197]. Libraries and sequencing were performed at the South Dakota State
University Genomics Sequencing Facility. Amplification of the V3-V4 amplicon (460bp)
of the 16S RNA gene was achieved using primers described in Klindworth et al. [198]:
16SAmpliconPCRForwardPrimer =
5'TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG
16SAmpliconPCRReversePrimer =
5'GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTA
ATCC. These primers include the Illumina overhang adapter sequences in their 5’ ends.
Amplification was carried out using KAPA HiFi HotStart Ready Mix (KAPABiosystems.
Wilminton, MA) using the following polymerase chain reaction (PCR) thermal profile:
3min @ 95C, 25 cycles (30sec @ 95C, 30 sec @ 55C, 30 sec @ 72C), 5 min @72C.
PCR clean-up was done with a SMARTer Apollo system (Takara Inc. Mountain View,
CA) using AMPure XP beads (Beckman Coulter. Indianapolis, IN). A second round of
PCR amplification was carried out to introduce individual Nextera XT (Illumina Inc. San
Diego, CA) indices in each library. This second amplification was carried out using
KAPA HiFi HotStart Ready Mix (KAPABiosystems. Wilminton, MA) using the
following PCR thermal profile: 3min @ 95C, 8 cycles (30sec @ 95C, 30 sec @ 55C,
30 sec @ 72C), 5 min @72C; PCR clean-up was done the same way as described for
the first PCR round. Sequencing was carried out in an Illumina MiSeq using vs 3
chemistry (3x300 bp).
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3.2.4 Bioinformatics and Statistical analyses
All bioinformatics analyses were performed using the Microbial Genomics
Module in CLC Genomics Workbench vs 12.0 (Qiagen). After trimming adaptors and
lower quality reads (q=20) the pared reads were joined. Samples with less than 90,000
reads were removed from further analysis. Resulting operational taxonomic units (OTUs)
were aligned to the GrainGenes database vs 13_5 at 97% similarity. Individual OTUs
with less than 100 reads were removed from further analysis. All samples underwent
taxonomic classification and were included in the complete OTU table (supplemental
Table 3-S2). Statistical comparisons between group pairs were carried out using a Wald
test; p values were False Discovery Rate (FDR) corrected.
For the body weight, differences between groups were determined by ANOVA,
followed by the Fisher’s multiple comparison procedure to identify differences in
treatment means. The results were expressed as means ± S.E.M. Mean differences were
considered significant at p < 0.05. Data were analyzed using SPSS 20.0.
3.3. Results
3.3.1. Effect of probiotic-enriched camel, cow, and goat milk on the gut microbiota
profiles and body weight gain
The effect of different milks on body weight is shown in Figure 3-2. Mice were
feed a standard LF/PP diet supplemented with the dairy products for 5 weeks. Mice in the
group supplemented with cow milk demonstrated a small, but significant (p=0.004)
weight gain when compared with the control group. However, mice fed diets
supplemented with either goat or camel milk did not have a significant body weight gain
compared to control animals.
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Analysis of fecal samples for changes in the gut microbiota in different
experimental groups is presented in Figure 3-3. Next generation gene sequencing of 16S
rRNA (3x300bp PE V3 + V4) from fecal samples was used to obtain data on the bacterial
relative abundance, which was analyzed at the level of order, family, and genus. The
groups supplemented with different milks were then compared. A significant reduction in
the relative abundance of order Clostridiales 191753 (p=0.01), Clostridiales 4455677
(p=0.02), family Clostridiaceae 268074 (p=0.02), and family Peptostreptococcaceae
276478 (p=0.01) was observed in the group supplementd with cow milk, while an
increase of order Clostridiales 199532 (p=0.03), Clostridiales 271602 (p=0.001), and
genus Anaerostipes 534926 (p=0.02) was demonstrated in the group supplemented with
camel milk as compared with the group supplemented with cow milk (Figure 3-3A). We
also found that the relative abundance of family Clostridiaceae 268074 and
Peptostreptococcaceae 276478 was significantly decreased in the camel milk group as
compared with the goat milk group (p=0.003 and p=0.003), respectively (Figure 3-3B).
The relative abundance of order Clostridiales 271602 and genus Anaerostipes 534926
was significantly higher in the goat milk group compared with the cow milk group
(p=0.03 and p=0.03), respectively, while a reduction in order Clostridiales 344198
(p=0.0003) was founded in animals supplemented with goat milk compared with the cow
milk group (Figure 3-3C).
A Venn diagram was established to clarify the overlap of OTUs (enriched for
certain OTUs) between the camel, cow, and goat milk supplemented groups. The total
significant richness in the dataset was 17 OTUs, with the most changes observed in the
camel milk group vs. the cow milk group (9 total OTUs) (Figure 3-4). We also observed
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that the body weight gain in the camel milk group exhibited a decreasing trend at day 21
and 35 (see Figure 3-2). These findings suggest that the gut microbiota enrichment can
be achieved via consumption of camel milk.

Figure 3-2. Percentage of body weight increase in mice fed diets supplemented with
cow, goat, or camel milk. Data are presented as mean ± SEM. n=5 per group. *p < 0.05,
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as compared between the indicated groups and determined by ANOVA.

Figure 3-3. Relative abundance of the gut microbiota at the order (o), family (f), and
genus (g) levels, as compared between the camel milk vs. cow milk groups (A), camel
milk vs. goat milk groups (B), and goat milk vs. cow milk groups (C). FDR p-value are
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p < 0.05, **p < 0.01, and ***p < 0.001.

Figure 3-4. The overlap (enrichment) of microbial species (OTUs) between the camel,
cow, and goat milk groups. The numbers indicate overlap in OTUs.
3.3.2. Effects of probiotic-enriched yogurt and cheese on the gut microbiota profiles
and body weight gain
The effects of probiotic-enriched yogurt and cheese of different origins (cow and
goat milk) on the gut microbiota and body weight were determined. Mice were fed LF/PP
diet supplemented with the probiotic dairy products for 5 weeks. Figure 3-5 shows that
the body weight gain of the probiotic cow cheese group exhibited a decreasing trend at
day 28 (p=0.08) and day 35 (p=0.07). The probiotic goat yogurt group demonstrated a
significant body weight gain compared to the probiotic cow cheese group (p=0.01) and
the cow cheese groups (p=0.03) at day 28. Individual body weight (g) and time (days)
measurements of mice fed diet supplemented with dairy products, are presented in
appendix Table 3-S1.
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Fecal samples were analyzed for changes in the gut microbiota of mice in the
experimental groups (Figure 3-6). The relative abundance of the order Clostridiales,
family Lachnospiraceae, genus SMB53, and species Ruminococcus gnavus were
significantly higher in the probiotic cow yogurt group vs. the cow yogurt group, while a
decrease in relative abundance of family Erysipelotrichaceae, Clostridiaceae, genus
Oscillospira, Clostridium, Ruminococcus, Aerococcus, species R. gnavus and
Clostridium perfringens were observed comparing the same groups (see Figure 3-6A).
Changes in the bacterial relative abundance were observed in comparisons
between the probiotic goat yogurt group and the goat yogurt group. A significant
decrease in abundance of order Clostridiales and family Lachnospiraceae were observed,
while relative abundance of order Clostridiales, genus Staphylococcus, Anaeroplasma,
Anaerostipes, and species R. gnavus was increased (see Figure 3-6B).
In the probiotic cow cheese group vs. the cow cheese group (Figure 3-7), the
relative abundance of order Clostridiales, family Ruminococcaceae, S24-7,
Lachnospiraceae, and species R. gnavus was significantly higher, whereas a decrease in
relative abundance of order Clostridiales, family Erysipelotrichaceae, Lachnospiraceae,
S24-7, genus Coprococcus, Oscillospira, and species R. gnavus was observed.
A Venn diagram was established to determine the overlap of OTUs between the
yogurt and cheese groups (Figure 3-8). The total significant richness in the dataset was
found for 16 OTUs in the cow yogurt group (Figure 3-8A), 13 OTUs in the goat yogurt
group (Figure 3-8B), and 30 OTUs in the cow cheese group. The most significant
enrichment was found in the probiotic cow cheese group vs. the cow cheese group (30
total OTUs) (Figure 3-8C). These findings suggest that the gut microbiota enrichment
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can be linked to consumption of the probiotic cow cheese and imply that this cheese can
be an efficient vector for the probiotic delivery.

Figure 3-5. Percentage of body weight increase in mice fed diets supplemented with
yogurt and cheese. Data are presented as mean ± SEM. n=5 per group. *p < 0.05 and
§

p < 0.08 (approaching significance), as compared between the indicated groups and

determined by ANOVA.
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Figure 3-6. Relative abundance of the gut microbiota at the order (o), family (f), genus
(g), and species levels (s), as compared between the probiotic cow yogurt group vs. the
cow yogurt group (A) and the probiotic goat yogurt group vs. the goat yogurt group (B).
FDR p-value are *p < 0.05, **p < 0.01, and ***p < 0.001.
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Figure 3-7. Relative abundance of the gut microbiota at the order (o), family (f), genus
(g), and species levels (s), as compared between the probiotic cow cheese group vs. the
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cow cheese group. FDR p-value are *p < 0.05, **p < 0.01, and ***p < 0.001.

Figure 3-8. The overlap (enrichment) of microbial species (OTUs) between the yogurt
and cheese supplemented groups. The numbers indicate overlap in OTUs.
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3.4. Discussion
The present studies demonstrated that gut microbiota enrichment can be achieved
via consumption of camel milk, as compared with cow and goat milk. In addition, a
significant gut microbiota enrichment was observed in mice supplemented with the
probiotic cow cheese. To the best of our knowledge, this is the first study that compared
the effects of supplementation with dairy products originating from different animals on
the gut microbiota composition.
The findings obtained indicate that, when compared with mice fed with cow milk,
mice fed a diet supplemented with camel milk demonstrate a decrease in body weight
gain (see Figure 3-2) accompanied by characteristic changes in the gut microbiota,
including an increase in order Clostridiales and genus Anaerostipes (see Figure 3-3A).
Importantly, these bacteria have been previously shown to produce short-chain fatty acids
(SCFAs), a bacterial fermentation product of dietary fiber, recognized to have wideranging effects on maintenance of health and host physiology [199-201]. We also found a
decreased abundance of Peptostreptococcaceae bacteria in the camel milk group.
Importantly, species in this family are positively associated with obesity and
inflammation [202-204].
The health benefits of camel milk may be partly explained by its functioning as a
prebiotic. Camel milk has a high overall nutritional value and high heat stability in the
process of preservation of raw milk by pasteurization [205, 206]. The induction of the
SCFAs producing gut bacteria via consumption of camel milk may lead to development
of nutritional strategy for weight loss and the prevention and treatment of obesity.
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Surviving passage over the host’s gastrointestinal tract is a critical event for any
probiotic. In this regard, we observed that the total significant richness in the dataset were
16 OTUs for the probiotic cow yogurt group vs. the cow yogurt, 13 OTUs for the
probiotic goat yogurt group vs. the goat yogurt group, and 30 OTUs for the probiotic cow
cheese group vs. the cow cheese group (see Figure 3-8C). These results indicate that the
probiotic supplement used in the study modified relative abundance of gut bacteria, some
of which can be associated with health benefits (particularly, a significantly increased
abundance of order Clostridiales due to the probiotic intervention; see Figure 3-7).
Therefore, cheese appears to be a suitable matrix for transferring probiotic bacteria into
the gastrointestinal tract, probably, due to the high buffering capacity of milk proteins
which will protect the microbial cells during transit (dense product structure may also
protect the bacteria against the acidic environment in the gastrointestinal tract [117-119]).
Clostridium butyricum supplementation triggered a shift in body weight gain with
a significant decrease in the probiotic cow cheese group compared with the probiotic goat
and cow yogurt groups (see Figure 3-5). We also found that the addition of this probiotic
to cow cheese improves gut microbiota manifesting in an increase in the relative
abundance of order Clostridiales, family Ruminococcaceae and Lachnospiraceae (see
Figure 3-7). These bacteria have been previously shown to produce butyrate [207, 208].
Butyrate (one of the main SCFAs) may be protective from developing of obesity and
metabolic disorder [181, 209]. Additionally, this probiotic in cheese was associated with
a significant reduction on the family Erysipelotrichaceae and genus Coprococcus. The
Erysipelotrichaceae abundance is high in obese individuals [210]. Furthermore, the
relative abundance of Coprococcus is increased by high-fat diet [211]. These are
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important considerations because they suggest the beneficial effect of the probiotic cow
cheese supplementation on maintaining normal body weight gain and facilitating weight
loss in obesity.
Overall, the results obtained and their bioinformatics analysis appear to support
the conclusion that camel milk and cow cheese enriched with Clostridium butyricum
probiotic are associated with potentially health beneficial changes of the mouse gut
microbiota. The findings also suggest that the consumption of camel milk and the
probiotic cow cheese may have beneficial effects on body weight gain, thus, providing
the basis for future clinical trials to investigate their effects in prevention of obesity.
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CHAPTER 4. Effects of Food at Home vs. Food Away from Home-Induced Changes
on Gut Microbiota and Immunological Status in Diabetes

Abstract: Gut microbiota dramatically affects our nutritional and immunological status.
However, linking diet to the structure and dynamic operation of microbial communities
and to human biology and pathobiology has proven elusive because of numerous
uncontrolled genetic and environmental variables. To study whether the food at home
(FAH), can help to reduce risk of developing diabetes by increasing abundance of the
beneficial bacteria, T regulatory (Treg) cells, and decreasing in inflammation-associated
bacteria, IL-17 producing cells, and blood glucose levels, 12 healthy volunteers were
randomly assigned into two diets, one based on food away from home (FAFH) and the
other on food at home (FAH). Two weeks later, fecal samples of the volunteers were
collected and analyzed, then transferred into antibiotic and non-antibiotic treated mice,
and their resistance to develop diabetes was measured. The results obtained and their
analysis support the conclusion that the FAH can help to reduce risk of developing
diabetes by increasing abundance of the beneficial bacteria (Bifidobacterium), Treg cells,
and decreasing levels inflammation-associated bacteria (Enterobacteriaceae), IL-17
producing cells, and blood glucose levels. The antibiotics used in this study minimized
result effects of FAH, emphasizing the link between gut microbiota, diet and immunity.

Keywords: food at home; food away from home; gut microbiota; diabetes; antibiotic; gut
microbiome transplantation; T regulatory cells; IL-17; glucose tolerance test
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4.1. Introduction
Gut microbiota dramatically affects the nutritional and immunological status of
both humans and animals [212, 213]. Recent studies have shown that FAFH rich on fat
and sugars are associated to dysbiosis (a microbial imbalance) and metabolic disease
promoting [214-216], while microbiota and bacterial products founded on individuals
with a diet high in fiber have anti-inflammatory properties [217-219]. Advances in “next
generation” DNA sequencing have dramatically increased our capacity to study microbial
communities associated with human body habitats (microbiota)[6, 7]. However, linking
diet to the structure and dynamic operation of microbial communities and, more
importantly, to the immunological status of the host has proven elusive because of
numerous uncontrolled genetic and environmental variables and the intrinsically
complicated nature of clinical trials. In the past, germ-free (GF) mice (animals born and
raised without any exposure to micro-organisms) have provide an excellent system for
controlling host genotype, diet and environmental conditions. In addition, they can be
colonized at specific life stages with different microbial communities and thus perform
comparative metagenomic studies of donor communities [123, 124]. However, raising
and maintaining a GF mice colony is challenging. Hence, a broad range antibiotic
treatment of mice is considered a viable alternative and has been successfully used
elsewhere. Antibiotics can be administered by either oral or intraperitoneal route [125127]. However, extrapolating results obtained in mice to humans is difficult because most
bacterial genera and species found in mice are different than those found in humans
[220]. Therefore, to develop an applicable mouse model, we propose to transplant human
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fecal microbiota into antibiotic and non-antibiotic treated C57BL/6 mice. Once a stable
“human-like” gut community is formed, these recipient animals will be evaluated for his
resistance to develop metabolic disease, such as diabetes. We believe this unique model
will allow us to unequivocally determine the effects of the diet on the microbial
community and link it to the etiology of several metabolic disorders.
The objective of this study is to evaluate effects of food at home (FAH) and food
away from home (FAFH) on human gut microbiota. In addition, to study whether the
FAH-induced microbial and immunity changes can protect mice against diabetes. The
results obtained and their analysis support the conclusion that the FAH can help to reduce
risk of developing diabetes by increasing abundance of the beneficial microbial species,
T regulatory cells, and decreasing IL-17 producing cell populations and blood glucose
levels.
4.2. Materials and Methods
4.2.1. Human study participants and diets
Twelve healthy male, college student participants, were recruited for the study
and assigned in a chronological order to the FAH group or FAFH group. FAH group
(n=6) followed food prepared at home for the duration of the study (e.g., vegetables,
fruits, nuts, seeds, legumes, brown rice, whole wheat breads, buttermilk, herbs, spices,
fish, poultry, eggs, yogurt, seafood and extra virgin olive oil). Additionally, avoiding
certain foods (e.g., soft drinks, added sugars, processed meat, refined grains, refined oils
and other highly processed foods, fast food restaurants and frozen meals). The FAFH
group (n=6) were the opposite of FAH and consumed at least 10 meals a week from
national fast food chains, daily for two weeks (Table 4-S1). All subjects gave their
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informed consent for inclusion before they participated in the study. The study was
approved by the SDSU IRB (Approval number: IRB-1512010).
Days
Wednesday

Restaurant Chains

Big Mac, large portion of French
fries, large Coca Cola

1330 calories

Domino's

Italian Sausage & Pepper Trio
Pizza, large Coca Cola

1410 calories

Burger King

Triple Whopper Sandwich, large
Coca Cola

1310 calories

McDonald's

Big Mac, large portion of French
fries, large Coca Cola

1330 calories

Domino's

Italian Sausage & Pepper Trio
Pizza, large Coca Cola

1410 calories

Burger King

Triple Whopper Sandwich, large
Coca Cola

1310 calories

McDonald's

Big Mac, large portion of French
fries, large Coca Cola

1330 calories

Domino's

Italian Sausage & Pepper Trio
Pizza, large Coca Cola

1410 calories

Burger King

Triple Whopper Sandwich, large
Coca Cola

1310 calories

McDonald's

Big Mac, large portion of French
fries, large Coca Cola

1330 calories

Domino's

Italian Sausage & Pepper Trio
Pizza, large Coca Cola

1410 calories

Burger King

Triple Whopper Sandwich, large
Coca Cola

1310 calories

McDonald's

Big Mac, large portion of French
fries, large Coca Cola

1330 calories

2/11/2016
Friday
2/12/2016
Saturday
2/13/2016
Sunday
2/14/2016
Monday
2/15/2016
Tuesday
2/16/2016
Wednesday
2/17/2016
Thursday
2/18/2016
Friday
2/19/2016
Saturday
2/20/2016
Sunday
2/21/2016
Monday
2/22/2016

Calories

McDonald's

2/10/2016
Thursday

Typical Meal
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Tuesday

Domino's

2/23/2016

Italian Sausage & Pepper Trio
Pizza, large Coca Cola

1410 calories

Table 4-S1. Characteristics of FAFH group, including days of intervention, list of
restaurant chains, typical meal, and calories.
4.2.2. Dietary assessments
At the study period, subjects were provided most of their food and instructed to
record the contents of their daily intake for two weeks. Each subject’s daily intakes of
energy, macronutrients, and other nutrients were calculated from the food record and
estimated by Food Processor Nutritional Analysis Pro version 11.4 (ESHA Research).
4.2.3. Animals, Antibiotic, fecal transplant, and diabetes inducing treatments
70-female 6-8-weeks old C57BL/6 mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). Upon arrival they were randomly grouped and keep in
SPF filter cages and sterile bedding. Mice were fed standard low fat, plant
polysaccharide-rich (LF/PP) diet ad libitum, and corresponding mice were treated with a
broad range of antibiotic (Vancomycin 5mg/ml, Neomycin 10 mg/ml, Metronidazole 10
mg/ml, and Amphotericin-B 0.1 mg/ml) by oral gavage, daily for two weeks. In addition,
water flasks were supplemented with 1g/L of ampicillin, to assure a consistent and
efficient bacterial depletion [127]. Afterward, mice were colonized with fecal samples
obtained from the human volunteers [221]. In order to reduce genetic variability, fecal
samples within the same group were pooled, diluted in PBS (1g in 10 ml) and introduced
by oral gavage (0.2 ml) into each recipient mice. Fecal samples were collected from the
mice before and 24h after colonization and weekly after that. One week later diabetes
were induced with streptozotocin (STZ), a compound that induces diabetes by inhibiting
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insulin production on pancreatic β-cells [222] (Table 4-1) (Figure 4-1). Body weight was
measured weekly, using top-loading balances with 0.01 g precision. The mice
experiments were performed at the Animal Research Wing (ARW) facilities under the
supervision of Michel Mucciante, DVM. The South Dakota State University Institutional
Care and Use Committee approved the protocols and maintenance of the animals
(IACUC Protocol number 15-094A).
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Treatment

Group
1
-

Antibiotic
cocktail
Fecal
Transplant
Experiment Diabete
al condition
s
Number of
10
mice

Group
2
-

Group
3
-

Group
4
-

Group
5
+

Group
6
+

Group
7
+

Group
8
+

FAH

FAFH

-

-

FAH

FAFH

-

Diabete
s
10

Diabete
s
10

5

Diabete Diabete Diabete
s
s
s
10
10
10

Table 4-1. Treatment groups and Experimental Design

Figure 4-1. Time line of the experimental treatments

5
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4.2.4. Flow cytometry and Cell preparation
Spleen tissues were collected from mice for the intracellular and external staining.
The red cells was removed by ACK lysing buffer. The splenic cell suspension was
stimulated and cultured for 5 h with leucocyte activation cocktail at 37 °C. Afterward, the
cell was stained with FITC-CD4 and APC-CD25 antibodies (eBioscience, San Diego,
CA) for 20 min at 4 °C. Then, cells were washed with FACS staining buffer (FB) (PBS
containing 2% FCS and 0.02% NaN3) (BD PharMingen). For intracellular staining, cells
were fixed and permeabilized using solution kit with BD GolgiStop™ (Cat. No. 554715),
cells were incubated with rat anti-mouse IL-17A and rat anti-mouse Foxp3 antibody at
4 °C for 30-60 min, in dark condition. Then, the cells were washed and re-suspended in
FB and acquired in a flow cytometer instrument. Data was analyzed using BD CSampler
Software, (BD Biosciences, Mountain View, CA, USA).
4.2.5. Glucose Tolerance Test (GTT)
After 16-hours of fasting, GTT was performed. For the GTT, 10 mice were
examined at each time point. Two g glucose per kg body weight was injected
intraperitoneal. Blood glucose levels were obtained immediately before the injection (0
min) and at 15, 30, 60, and 120 min after glucose injection. The blood samples (5-µL)
were collected via a small incision, made at the tip of the tail vein according to the
manufacturer’s instructions (FreeStyle glucose analyzer, Witney, Oxon, UK).
4.2.6. DNA Extraction and Real-Time PCR Analysis
A total of 24 human stool samples, twelve from each group (FAFH-FAH), were
included in this study. DNA was extracted from stool sample by using microbial DNA
extraction method (ZR Fecal DNA MiniPrep™) as previously described by [197]. All
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primers and nucleotide sequences used for real-time PCR are shown in (Table 4-2). PCR
amplification was carried out by (Agilent Technologies M x 3005P qRT-PCR) in the
following conditions: 95 °C for 10 min, followed by 40 cycles of 95 °C for 30 s, 60 °C
for 30 s, and 72 °C for 30 s. Power SYBR Green PCR Master Mix (AB # 4367659,
10µl for 1 reaction). Primer (16 µM/µl- 0.5 F + 0.5 R for 1 reaction) and 9µl of each
cDNA sample. All data were analyzed by using the comparative CT method [223]. As
following:

Table 4-2. Primer sequences for real-time PCR

90

4.2.7. Statistical analysis
A one-way ANOVA with independent samples t-test was used for group
comparison of the T regulatory cells, IL-17 producing cells, glucose tolerance test, and
body weight. Unpaired t-test was used for the group comparison between FAFW and
FAH for nutrients intake and gut microbiota. The results were expressed as means ± S.E,
and mean differences were considered significant at p < 0.05. Data were analyzed using
(SPSS Statistics, v. 25).

4.3. Results
In this study, we evaluated effects of FAH and FAFH diets on human gut
microbiota. In addition, we study whether the FAH diet-induced microbial changes can
protect mice against diabetes by modulation of the immune system. Twelve participants
were recruited in the study (6 in the FAH group and 6 in the FAFH group). The average
age and body mass index BMI of the study participants was 26.6 years and 26.9 (kg/m2)
respectively. No participants dropped out of the study during the two weeks intervention
period.
4.3.1. Estimated Nutrients Intake at FAH and FAFH Groups of Intervention
Periods
At the study period, subjects were provided most of their food and instructed to
record the contents of their daily intake for two weeks. Evaluation of dietary intakes of
the study subjects through the study revealed no significant variations in calories,
carbohydrates, and cholesterol intakes between the two groups (Table 4-3). As expected,
due to a consumption of food prepared at home for the duration of the study, there was a
significant increased on total dietary fiber intakes compared to FAFH group (p < 0.001).
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In addition, there were a significant increased on the fat (p < 0.05), saturated fat
(p < 0.004), and trans fatty acid (p < 0.03) intakes in FAFH group compared to FAH.
Also, a significant reduction in the intakes of monounsaturated fat (p < 0.05) and
polyunsaturated fat (p < 0.03) were observed in FAFH group compared to FAH group
(Table 4-3). These results indicate that the FAH diet used in the study altered nutrients of
intake, some of which can be associated with health benefits (particularly, significantly
increased nutrients of dietary fiber and mono/polyunsaturated fat due to the FAH diet
intervention).
Nutrients

FAH

FAFH

p * : FAH vs FAFH

Calories (kcal/d)

2107 ± 97

2164 ± 50

NS

Protein (g/d)

105 ± 12

72 ± 6

<0.05

Carbohydrates (g/d)

269 ± 45

257 ± 14

NS

Total Dietary Fiber (g/d)

29 ± 2

10 ± 1

<0.001

Fat (g/d)

73 ± 10

100 ± 5

<0.05

Saturated Fat (g/d)

20 ± 4

42 ± 4

<0.004

Monounsaturated Fat (g/d)

17 ± 4

5±4

<0.05

Polyunsaturated Fat (g/d)

9±1

2±2

<0.03

0.008 ± 0.001

1 ± 0.41

<0.03

328 ± 88

253 ± 29

NS

Trans Fatty Acid (g/d)
Cholesterol (mg/d)

Table 4-3. Estimated nutrients intake at FAH and FAFH groups of intervention periods.
FAH, food at home; FAFH, food away from home; NS, not significant. The results are
expressed as mean ± SE. p* Obtained from independent t-test (SPSS Statistics, v. 25).
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4.3.2. Effect of FAFH and FAH diets on human gut microbiota
Gut microbiota analysis was conducted using quantitative PCR with specific
primers for Bifidobacterium and Enterobacteriaceae. The gene expression of
Bifidobacterium was noticeably enriched after FAH intervention (Figure 4-2A), while
the Enterobacteriaceae showed a decreasing trend after FAH intervention (Figure 4-2B).
Our study indicates that short-term (2 weeks) FAH intervention results in modulation of
the gene expression, accompanying by an increase in beneficial bacteria
(Bifidobacterium) and a decrease in inflammation-associated bacteria
(Enterobacteriaceae).

Figure 4-2. Mean fold change of gene expression was calculated using the comparative
CT method (2ΔΔCt) between the intervention group, for Bifidobacterium (A), and
Enterobacteriaceae (B). The results are expressed as mean ± SE. Unpaired t-test was
used for the group comparison (SPSS Statistics, v. 25).
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4.3.3. Effect of FAFH and FAH diets on Gp49b, 2B4, Reg3b, Ptgs2, Cxcr3, Tnfa,
and Il6 parameters
Parameter analysis was conducted using quantitative PCR with specific primers
for Gp49b, 2B4, Reg3b, Ptgs2, Cxcr3, Tnfa, and Il6. The results attempt to confirm the
effect of FAFH and FAH diets on this parameters, such a links of this parameters have
been incorporated in health and diseases. The quantity of Gp49b, 2B4, Reg3b, and Ptgs2
were significantly higher in the FAFH than that in FAH subjects (Figure 4-3. A, B, C,
and D) (p=0.01) (p=0.03) (p=0.05) (p=0.04) respectively. While the level of Cxcr3 and
Tnfa were significantly higher in the FAH group compared to the FAFH (Figure 4-3. E
and F) (p=0.05) (p=0.01) respectively. No significant difference was perceived on fold
change of Il6 between the FAFH and FAH subjects, even though this fold change was
relatively abundant in the FAFH group compared to the FAH group (Figure 4-3G).
These results indicate that the FAH diet used in the study altered gene expression of
parameters, some of which can be associated with health benefits (particularly,
significantly decreased parameters of Glycoprotein (Gp49b), Regenerating Islet-Derived
3 Beta (Reg3b), and Prostaglandin-Endoperoxide Synthase 2 (Ptgs2) due to the FAH diet
intervention).
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Figure 4-3. Mean fold change of gene expression was calculated using the comparative
CT method (2ΔΔCt) between the intervention group, for Gp49b (A), 2B4 (B), Reg3b (C),
Ptgs2 (D), Cxcr3 (E), Tnfa (F), and Il6 (G). The results are expressed as mean ± SE.
p < 0.05. Unpaired t-test was used for the group comparison (SPSS Statistics, v. 25).

*

4.3.4. Effect of CD4+CD25+Foxp3+ T regulatory cells
We here studied and compared whether production of CD4+CD25+Foxp3+ T
regulatory cells can be influenced by antibiotic or non-antibiotic treatment, diabetes, FAT
and FAFH diet. T regulatory cells are a subpopulation of T cells which have a role in
suppressing or controlling other cells, to prevent autoimmune disease [224, 225]. The
results obtained indicate that there were no statistically significant differences between
the groups of (Control, Antibiotic + Fecal Transplant FAH + Diabetes, and Antibiotic +
Fecal Transplant FAFH + Diabetes) (Figure 4-4A). On the other hand, the percentage of
CD4+CD25+Foxp3+ T regulatory cells was significantly increased in Fecal Transplant
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FAH + diabetes group compared to Fecal Transplant FAFH + diabetes (p=0.009). Also,
from Control compared to Fecal Transplant FAH + diabetes and Fecal Transplant FAFH
+ diabetes group (p=0.01) (p=0.001) respectively (Figure 4-4B). The findings obtained
demonstrate that FAH diet is effective for increasing the levels of CD4+CD25+Foxp3+ T
regulatory cells, but not in mice treated with antibiotic.
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Figure 4-4. Percentage of Foxp3+ cells within CD4+CD25+ T cells in each Control, Fecal
Transplant FAH + Diabetes, and Fecal Transplant FAFH + Diabetes groups (n = 10) is
shown. For antibiotic (A) and non-antibiotic treatment groups (B). The results are
expressed as mean ± SE. A one-way ANOVA with independent t-test was used for the
group comparison (SPSS Statistics, v. 25).
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4.3.5. IL-17 production
We then studied and compared whether production of IL-17 cells can be
influenced by antibiotic or non-antibiotic treatment, diabetes, FAH and FAFH diet. “IL17 cells are CD4+ T-helper cells that produce IL-17 family cytokines and other
inflammatory cytokines. IL-17 producing cells are implicated in chronic inflammation
and are considered to drive some autoimmune diseases”[226]. The results obtained
indicate that there were no statistically significant differences between the groups of
(Control, Antibiotic + Fecal Transplant FAH + Diabetes, and Antibiotic + Fecal
Transplant FAFH + Diabetes) (Figure 4-5A). On the other hand, the percentage of IL-17
cells was significantly decreased in Fecal Transplant FAH + Diabetes group compared to
Control, while Fecal Transplant FAH + diabetes group pointed to a decreasing trend in
IL-17 cells percentage compared to Fecal Transplant FAFH + Diabetes group (Figure 45B). The findings obtained demonstrate that FAH diet is effective for decreasing
production of IL-17 cells, but not with mice treated with antibiotic.
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Figure 4-5. Percentage of IL-17 cells in each Control, Fecal Transplant FAH + Diabetes,
and Fecal Transplant FAFH + Diabetes groups (n = 10) is shown. For antibiotic (A) and
non-antibiotic treatment groups (B). The results are expressed as mean ± SE. A one-way
ANOVA with independent t-test was used for the group comparison (SPSS Statistics, v.
25).
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4.3.6. Glucose Tolerance Test (GTT)
Blood glucose levels were obtained immediately before the injection (0 min) and
at 15, 30, 60, and 120 min after glucose injection. After the intraperitoneal injection of
glucose, blood glucose levels were increased in each treatment group. At 15 min, the
blood glucose level was significantly lower in the Fecal Transplant FAH + diabetes group
than in the Fecal Transplant FAFH + diabetes group (p=0.01). In addition, it was also
significantly lower in the Fecal Transplant FAH + diabetes group than in Control and
Fecal Transplant FAFH + diabetes groups at 30 min (p=0.03) (p=0.02) respectively
(Figure 4-6A). On the other hand, the blood glucose levels of the group treated with
antibiotic did not significantly differ between the groups (Figure 4-6B). The findings
obtained demonstrate that FAH diet is effective for decreasing blood glucose levels, but
not with mice treated with antibiotic.
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Figure 4-6. Glucose tolerance test in each Control, Fecal Transplant FAH + Diabetes,
and Fecal Transplant FAFH + Diabetes groups (n = 10) is shown. For non-antibiotic (A)
and antibiotic treatment groups (B). The results are expressed as mean ± SE. A one-way
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ANOVA with independent t-test was used for the group comparison (SPSS Statistics, v.
25). 4.3.7. Body Weight and Days of Intervention
Body weight was measured weekly, using top-loading balances with 0.01 g
precision. As seen in figure 4-7, there were no significant difference on the body weight
between the groups treated and not treated with antibiotic (Figure 4-7A) (Figure 4-7B).
However, the body weight gain of the Fecal Transplant FAH + Diabetes group exhibited
a decreasing trend at day 22.
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Figure 4-7. Body weight in each Control, Fecal Transplant FAH + Diabetes, and Fecal
Transplant FAFH + Diabetes groups (n = 10) is shown. For non-antibiotic (A) and
antibiotic treatment groups (B). The results are expressed as mean ± SE. A one-way
ANOVA with independent t-test was used for the group comparison (SPSS Statistics, v.
25).
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4.4. Discussion
The study was designed to evaluate the effects of food at home (FAH) and food
away from home (FAFH) on human gut microbiota. In addition, to study whether the
FAH diet-induced microbial and immunity changes can protect mice against diabetes
following the transplantation of human fecal microbiota into antibiotic and non-antibiotic
treatment mice. While FAH diet have been shown to improve markers of metabolic
syndrome and gut microbiota [227, 228]. However, this study was comprehensively
evaluating effects of FAH and FAFH diets in gut microbiota, immune function, body
weight, diabetes developing in antibiotic and non-antibiotic treatment mice.
An important finding of the study is that the FAH group resulted in a noticeable
increase in abundance of Bifidobacterium strains in the gut after a 2-weeks intervention.
It has been stated that some strains of Bifidobacterium can be referred as healthy gut
microbiota along with anti-diabetes agents [229, 230]. Furthermore, Enterobacteriaceae
family was noticeably decreased after the FAH diet intervention (see Figure 2-2).
Previous studies have stated that these family are associated with inflammation-driven
bacterial dysbiosis and positively correlated with diabetes [231-233]. Therefore, the study
confirmed that short-term (2 weeks) FAH intervention results in an increase in beneficial
bacteria (Bifidobacterium) and a decrease in pro-inflammatory bacteria
(Enterobacteriaceae).
Dietary patterns containing FAH diet are now broadly recognized to be critical for
protection against various diseases with an inflammatory nature. In contrast, FAFH diet
are recognized to apply various harmful effects [234, 235]; including its metabolic and
inflammatory related alterations in CD4+CD25+Foxp3+ T regulatory cells, and IL-17
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[236]. Therefore, we examined the possible alterations caused by FAH diet to this
populations and there resistance for development of diabetes. Higher percentage of
CD4+CD25+Foxp3+ T regulatory cells were observed in Fecal Transplant FAH + diabetes
group compared to Fecal Transplant FAFH + diabetes (see Figure 4-4B). In the Fecal
Transplant FAH + diabetes group, increasing percentage of CD4+CD25+Foxp3+ T
regulatory cells was associated with decreasing blood glucose levels (see Figure 4-6A).
However (and somewhat paradoxically), higher percentage of CD4+CD25+Foxp3+ T
regulatory cells at control group compared to Fecal Transplant FAH + diabetes and Fecal
Transplant FAFH + diabetes were also observed (see Figure 4-4B). The administration of
diabetes (STZ) and the effect of longstanding hyperglycemia can promote a strong
inflammatory progression in the islets which is toxic to beta cells. Thus, increasing the
number of T regulatory cells in the spleen were as a results of controlling damage of the
tissue [237]. The role of IL-17 producing cell in FAH diet has not been totally examined.
Thus, our data point out an increased on the frequencies of IL-17 cell in control group
compared to Fecal Transplant FAH + diabetes; which also involve in the pathogenesis of
diabetes.
In the present study, the FAH diet used in the study altered gene expression of
parameters, some of which can be associated with health benefits (particularly,
significantly decreased parameters of Gp49b, Reg3b, and Ptgs2 due to the FAH diet
intervention)[238-240]. An interesting finding was the reduced glucose intolerance in
FAH fecal transplant, Gp49b, Reg3b, and Ptgs2 –deficient mice. Therefore, Gp49b,
Reg3b, and Ptgs2 might be important for the development of type 2 diabetes which
requires further investigation.
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Our data point out that antibiotic administration minimized result effects of FAH
diet on both CD4+CD25+Foxp3+ T regulatory cells, IL-17 production, and glucose
tolerance test, compared to those groups of non-treated with antibiotic, such an antibiotics
can change the population or balance of composition and more compromise mucosal
immunity of the gut microbiota [241].
Evaluation of dietary intakes of the study subjects through the study revealed a
significant variations between the two groups (Table 4-3). As expected, due to a
consumption of food prepared at home FAH, there was a significant increased on total
dietary fiber intakes compared to FAFH group. These results indicate that the FAH diet
used in the study altered nutrients of intake, some of which can be associated with health
benefits (particularly, significantly increased nutrients of dietary fiber due to the FAH
diet intervention). Importantly, these dietary fiber have been previously shown to produce
short-chain fatty acids (SCFAs), a bacterial fermentation product of dietary fiber,
recognized to have wide-ranging effects on maintenance of health and host physiology
[199-201].
The design of the study has allowed us to detect important effects of FAH vs.
FAFH-induced changes on gut microbiota and immunological status in diabetes in the
relatively limited number of participants in this study. However, the used of dietary
records are affected by error and has limitation “due mainly to the tendency of subjects to
report food consumption close to those socially desirable. Further problems are related to
the high burden posed on respondents. It can also influence food behavior in respondents
in order to simplify the registration of food intake and some subjects can experience
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difficulties in writing down the foods and beverages consumed or in describing the
portion sizes” [242].
The results obtained and their analysis support the conclusion that the FAH can
help to reduce risk of developing diabetes by increasing abundance of the beneficial
bacteria (Bifidobacterium), T regulatory cells, and decreasing in inflammation-associated
bacteria (Enterobacteriaceae), IL-17 producing cell populations, and blood glucose
levels. The antibiotics used in this study minimized result effects of FAH diet. Further
additional studies using germ-free mice are needed to better understand the role of gut
microbiota in the modulation of the immune system and its contribution to inflammation
and autoimmunity diseases.
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CHAPTER 5. General Discussion
The rising prevalence of obesity and metabolic disorders and its harmful health
consequences are of increasing global concern [1, 2]. The health effects of being
overweight and obese are not without controversy [243, 244], but large pooling studies
have shown increased risks for cardiovascular diseases, diabetes, cancers and chronic
kidney diseases[245, 246]. Although public health campaigns and an increasingly healthconscious general population has succeeded in slowing the growth rate of obesity in
developed countries, much more has to be done in order to reach the WHO target of
halting the rise in obesity by 2025. To date, there is not a single country with welldocumented downwards trends in obesity rates. Therefore, rigorous data-based plans
combining a healthy diet with the promotion of a more active lifestyle are needed in order
to be evaluated and translated into national obesity control programs.
From a metabolic point of view, obesity is the consequence of a prolonged
imbalance between energy intake and expenditure caused by a very complex interplay
between genetics, nutrition and environmental factors [247, 248]. Recent studies have
shown that gut microbiota plays a critical role in the pathogenesis of obesity and
associated diseases [249]. Such a link was first suggested after observing that
colonization of lean mice with cecal microbiota from obese mice resulted in a greater
increase in body fat when compared with microbiota from lean mice [18]. Subsequent
studies in both mice and humans confirmed that obesity was accompanied by an altered
gut microbiota [153, 250-252]. Therefore, the gut microbiota has become a target for
obesity and metabolic disease prevention. Indeed, data from both experimental and
clinical studies suggest that modulation of gut microbiota through administration of
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probiotics (normally Lactobacillus or Bifidobacterium) may be an effective strategy to
treat metabolic diseases, although other studies failed to find a correlation between
probiotic supplements and an improved health status [253]. Besides probiotics, the gut
microbiota can be modulated through administration of prebiotics, food ingredients that
resist degradation in the upper digestive tract and selectively enhance the growth and/or
activity of one or few resident bacteria and can improve insulin sensitivity, lipid
metabolism and low-grade chronic inflammation [254, 255]. Consequently, synbiotics, or
the combination of both pre and probiotics, have the potential to induce a more
substantial effect on gut microbiota and host health and are therefore the focus of a big
research effort [256].
Probiotic bacteria have often been assessed as dietary supplements or in dairy
products, such as yogurt or kefir [115, 116]. We believe that because of its nutritional
values and longer shelf life, fermented cheese would be an ideal vector for the delivery of
probiotics. Cheese is a good matrix for transferring probiotic bacteria into the
gastrointestinal tract, due to the buffering capacity of the milk proteins which will protect
the cells during transit; this is mainly due to their higher fat content and denser structure
that may protect the bacteria against the acidic environment of the gastrointestinal tract
[117-119].
It was demonstrated that whole grain diet can decreased risk of numerous
lifestyle-associated diseases including type 2 diabetes, for the reason that “microbial
degradation of whole grains, rich in dietary fibers, leads to production of short-chain fatty
acids, which may exert beneficial effects on the host metabolism” [257]. However, it is
not been thoroughly investigated to what extent beneficial effects of whole grain and
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food at home consumption are associated with the gut microbiota and immunological
status.
In view of the potential effects of diet, prebiotics, and probiotics on gut
microbiota in obesity and metabolic disorders, the main hypothesis tested in these studies
was that the whole grain diet, dairy products, pre and probiotics will modulate gut
microbiota by increasing abundance of the beneficial microbial species and the
supplement may also have beneficial effects on body composition, immune system, and
metabolic parameters in obesity. The aims of this dissertation were (1) to evaluate effects
of the synbiotic supplement containing Bifidobacterium and Lactobacillus strains on the
human-gut microbiota in relation to changes in body composition and metabolic
biomarkers in obesity, (2) to characterize the effect of dairy products (cow, goat, and
camel milk and fermented cheese and yogurt originated from cow milk and containing
the well-established probiotic Clostridium butyricum) on taxonomic composition and
relative abundance of the mouse gut microbiota and body weight, (3) to study the effects
of food at home and food away from home diets on human gut microbiota. In addition, to
study whether the food at home-diet-induced microbial and immunity changes can
protect mice against diabetes.
The data presented in Chapter 2 indicate that weight loss in human subjects
participating in a high-protein, low-carbohydrate, energy-restricted eating weight loss
program is accompanied by changes in gut microbiota that can be associated with
increased genotoxicity [144]. The synbiotic used in this study modulated the human gut
microbiota by increasing abundance of the microbial species that can be considered to be
of benefit to their host; it was also associated with positive effects on metabolic
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parameters in obesity. A combination of the four strains of Bifidobacterium and
Lactobacillus acidophilus in the synbiotic supplement resulted in a significant increase in
abundance of these probiotic genera in the gut after a 3-month intervention.
Bifidobacterium is largely considered a positive member of the microbial community and
furthermore, there has been some association with anti-obesity effects [162, 166, 167]. In
addition to this, further modulation of the microbiota was observed, for example,
Prevotella and Gardnerella genera were significantly decreased after the synbiotic
intervention. Previous studies have reported that these genera are associated with chronic
inflammatory conditions and positively correlated with obesity [168-170]. Therefore, the
reduction in these genera could help to modulate the balance to improve metabolism
within the host. Special caution is warranted when analyzing the data referring to
Prevotella, a complex genus linked both to health and disease and maybe influenced by
race/ethnicity [171]. However, statistically significant differences in the community
composition of gut microbiota between groups (synbiotic vs. placebo) and time points
(end vs. beginning of trial) using parameters of alpha-diversity and beta-diversity were
not observed. Our data is compatible with a recent study that did not found a relationship
between severe caloric restriction and changes in alpha-diversity[172]. In addition,
correlation and regression analyses did not indicate statistically significant or apparently
beneficial associations between species contained in the synbiotic supplement
(Bifidobacterium and Lactobacillus) and body composition parameters, including at the
end of synbiotic intervention. Interestingly, the changes over time in body mass, BMI,
waist circumstance, and body fat mass demonstrated a positive correlation trend with
Bifidobacterium abundance in the synbiotic group, while changes in body fat mass were
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negatively correlated with Lactobacillus abundance in the placebo group. However,
positive associations between relative abundance of Bifidobacterium and several body
composition parameters appear to point to the unfavorable role of these bacteria in
promoting weight loss, although any potential benefits of this genera could be masked by
the high-protein diet used in the study. High protein intake induces proteolytic
fermentation in the gut with synthesis of compounds that have been implicated in the
development of obesity and metabolic syndrome and modulating the gut microbiota [140142, 173] and the production of toxic metabolites [174]. Several studies have also found
that an increase in Bifidobacterium and Lactobacillus abundance is correlated with both
pro- and anti-obesity effects in obese human subjects [175, 176], thus complicating the
interpretation of the results. Individual differences in energy extraction may contribute to
explain the observed differences [177]. Additionally, Bifidobacterium have been linked
with improved barrier function in overweight individuals, thus adding a potential
beneficial mechanism of action [81]. Therefore, more studies are needed to fully
understand the observed divergences and correctly identify human subpopulations
susceptible to benefit from synbiotic intervention.
Regression analysis performed to correlate microbial abundance of species
contained in the synbiotic supplement with biomarkers of obesity found a novel
significant association between a decrease over time in HbA1C percentage and an
increase in Lactobacillus abundance, particularly in the synbiotic group. This is an
important observation because it demonstrates the beneficial effect of increasing
Lactobacillus abundance on potentially reducing blood glucose levels. Negative
associations between Megasphaera abundance and Eubacterium ruminantium abundance
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with HbA1C levels were observed in the synbiotic group at the end of trial. Eubacterium
ruminantium are xylanolytic bacteria (i.e., producing xylanase following dietary fiber
fermentation) and Megasphaera bacteria utilize lactate [178], which can underlie
potential relationship of these species to decreasing blood glucose levels [179, 180].
However, within the trial following the synbiotic a decrease in Megasphera was
observed, an increase in Eubacterium ruminantium. This could imply that the synbiotic
intervention and associated microbial changes could be linked to maintaining a normal
blood glucose levels in obesity.
It should also be considered that the microbial shifts observed in this study may
be associated with a positive impact on microbial fermentation within the large intestine.
Whilst the microbial changes observed following synbiotic intervention included an
increase in Ruminococcus, a genera known to produce butyrate. Butyrate is a short chain
fatty acid that provides and energy source for the colonocytes, as a histone deacetylase
inhibitor this SCFA is linked to anti-cancer effects, hence could offer protection against
some of the metabolites that are produced within a high protein diet. SCFA’s have also
recently been associated with protection against type 1 diabetes [181]. In addition to this
lactobacilli and bifidobacteria are associated with positive effects of colonic health and
following synbiotic intervention have been associated with reducing fecal water
genotoxicty, which is considered a biomarker for colon cancer [182]. Therefore, whilst
within the weight-loss diet employed the synbiotic treatment may have had a limited
impact on the weight-loss parameters, it is possible that the changes in the microbiota
could help to reduce detriments associated with a high protein diet.
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Manipulation of the gut microbiota through dietary intervention and probiotic
supplements can be a promising strategy for the prevention and treatment of metabolic
syndrome and obesity. Therefore, data presented in Chapter 3 demonstrated that gut
microbiota enrichment can be achieved via consumption of camel milk, as compared with
cow and goat milk. In addition, the significant gut microbiota enrichment was observed
in mice supplemented with the probiotic cow cheese, as compared with the probiotic cow
and goat yogurt. To our knowledge, this is the first study that compared the effects of
supplementation with dairy products originating from different animals on the gut
microbiota composition, particularly, the study of camel milk and fermented cheese. The
present study indicated that, when compared with mice fed with cow milk, mice fed a
diet supplemented with camel milk demonstrate a decrease in body weight gain
accompanied by characteristic changes in gut microbiota, including an increase in order
Clostridiales and genus Anaerostipes. Importantly, these bacteria have been previously
shown to produce short-chain fatty acids (SCFAs) a bacterial fermentation product of
dietary fiber, recognized to have wide-ranging effects on maintenance of health and host
physiology [199-201]. We also found a decreased abundance of Peptostreptococcaceae
bacteria in the camel milk group. Importantly, species in this family are positively
associated with obesity and inflammation [202-204]. The health benefits of camel milk
may be partly underlined by its functioning as prebiotic. Camel milk has a high overall
nutritional value and high heat stability in the process of preservation of raw milk by
pasteurization [205, 206]. The induction of the SCFAs producing gut bacteria via
consumption of camel milk may lead to development of nutritional strategy for weight
loss and the prevention and treatment of obesity.
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Surviving passage over the host’s gastrointestinal tract is a critical event for any
probiotic. In this regard, we observed that the total significant richness in the dataset were
16 OTUs for the probiotic cow yogurt group vs. the cow yogurt, 13 OTUs for the
probiotic goat yogurt group vs. the goat yogurt group, and 30 OTUs for the probiotic cow
cheese group vs. the cow cheese group. These results indicate that the probiotic
supplement used in the study modified relative abundance of gut bacteria, some of which
can be associated with health benefits (particularly, significantly increased abundance of
order Clostridiales due to the probiotic intervention). Therefore, cheese appear to be a
good matrix for transferring probiotic bacteria into the gastrointestinal tract, probably,
due to the high buffering capacity of milk proteins which will protect the microbial cells
during transit (high fat cheese content and dense product structure may also protect the
bacteria against the acidic environment in the gastrointestinal tract [117-119]).
Clostridium butyricum supplementation triggered a shift in body weight gain with a
significant decrease in probiotic cow cheese group compared with the probiotic goat and
cow yogurt groups. We also found that the addition of this probiotic to cow cheese
improves gut microbiota manifesting in an increase in the relative abundance of order
Clostridiales, family Ruminococcaceae, and Lachnospiraceae. These bacteria have been
previously shown to produce butyrate [207, 208]. Butyrate (one of the main SCFAs) may
be protective from developing of obesity and metabolic disorder [181, 209]. Additionally,
this probiotic in cheese was associated with a significant reduction on the family
Erysipelotrichaceae and genus Coprococcus. The Erysipelotrichaceae abundance is high
in obese individuals [210]. Furthermore, the relative abundance of Coprococcus is
increased by high-fat diet [211]. These are important considerations because they suggest
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the beneficial effect of the probiotic cow cheese supplementation on maintaining normal
body weight gain and facilitating weight loss in obesity.
The data presented in Chapter 4 indicate that the food at home, can help to
reduce risk of developing diabetes by increasing abundance of the beneficial bacteria
(Bifidobacterium), T regulatory cells, and decreasing in inflammation-associated bacteria
(Enterobacteriaceae), IL-17 producing cells, and blood glucose levels. Importantly, the
FAH diet used in the study altered gene expression of novel parameters, some of which
can be associated with health benefits (particularly, significantly decreased parameters of
Gp49b, Reg3b, and Ptgs2 due to the FAH diet intervention)[238-240]. An interesting
finding was the reduced glucose intolerance in FAH fecal transplant, Gp49b, Reg3b, and
Ptgs2 –deficient mice. Consequently, Gp49b, Reg3b, and Ptgs2 might be important for
the development of type 2 diabetes which requires further investigation. Our data also
point out that antibiotic administration minimized result effects of FAH diet on both
CD4+CD25+Foxp3+ T regulatory cells, IL-17 producing cells, and glucose tolerance test,
compared to those groups of non-treated with antibiotic, such an antibiotics can change
the population or balance of composition and more compromise mucosal immunity of the
gut microbiota [241]. Further additional studies using germ-free mice are needed to better
understand the role of gut microbiota in the modulation of the immune system and its
contribution to inflammation and autoimmunity diseases.
In summary, this dissertation explores a scope of studies on the effects of diet on
gut microbiota and health outcomes including obesity and metabolic disorders taking into
perspective diets such as food at home, dairy products, high-protein, low-carbohydrate,
prebiotic and probiotic. The main outcome of our studies is identification of an effective
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and novel approach for the prevention and treatment of obesity and metabolic disorders
that is based on modulating the human/mouse gut microbiota and increasing abundance
of the microbial species that can be considered to be of benefit to their immune system
and host.
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Table 2-S3. Body composition parameters, including DXA scans data. A and B before
sample numbers indicate the synbiotic and placebo groups, respectively.
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der
F

A
ge
48

HbA1C_p Body_m
ercent
ass_kg
4.5
63.8

BMI_kg_
per_m2
26.4

WC
_cm
97

Body_Fat_
percent
33.9

A10

F

66

5.5

70.3

28.4

93

41.6

A11

M

45

4.9

82.5

26.9

102

NA

A3

F

37

4.8

104

41.9

120

48.5

A4

F

47

4.3

80.8

30.4

94

44.4

A5

M

43

5.3

92.5

27.7

104

29.3

A6

F

42

5.2

91

34.5

108

47.7

A7

F

60

5.7

89.5

37.3

101

45.1

A8

M

40

5.3

78.9

27.3

96

22.6

A9

F

50

5.1

81.6

34

111

NA

Place
bo
Place
bo
Place
bo
Place
bo
Place
bo
Place
bo
Place
bo
Place
bo
Place
bo

EndOf
Trial
EndOf
Trial
EndOf
Trial
EndOf
Trial
EndOf
Trial
EndOf
Trial
EndOf
Trial
EndOf
Trial
EndOf
Trial

B1

M

51

5.9

133

35.7

123

33

B10

F

79

5

77.7

27.7

105

40.3

B11

F

34

4.9

68

24.2

88

NA

B3

F

45

4.6

76.2

27.7

99

42.8

B4

F

39

4.9

86.6

26.9

85

38

B5

F

51

4.6

79.2

30

94

35

B6

F

39

5.2

100.6

32.8

108

41.4

B7

F

50

5

93.5

36.5

108

46.1

B8

M

22

5.3

119

32.3

115

NA
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Place
bo

EndOf
Trial

B9

F

60

5.2

Treat
ment
Synbi
otic
Synbi
otic
Synbi
otic
Synbi
otic
Synbi
otic
Synbi
otic
Synbi
otic
Synbi
otic
Synbi
otic
Synbi
otic

Timep
oint
Baseli
ne
Baseli
ne
Baseli
ne
Baseli
ne
Baseli
ne
Baseli
ne
Baseli
ne
Baseli
ne
Baseli
ne
Baseli
ne

Subj
ect
A1

Gen
der
F

A
ge
48

A10

F

A11

Place
bo
Place
bo
Place
bo
Place
bo
Place
bo
Place
bo
Place
bo
Place
bo
Place
bo
Place
bo

Baseli
ne
Baseli
ne
Baseli
ne
Baseli
ne
Baseli
ne
Baseli
ne
Baseli
ne
Baseli
ne
Baseli
ne
Baseli
ne

66.3

27.6

86

NA

HbA1C_p Body_m
ercent
ass_kg
5.6
66.4

BMI_kg_
per_m2
27.5

WC
_cm
98

Body_Fat_
percent
35.6

66

5.3

84.8

34.2

106

48.5

M

45

5.3

93

30.3

113

NA

A3

F

37

5.5

113

45.6

127

49.9

A4

F

47

5.1

82.9

31.2

102

45.5

A5

M

43

5.4

97.5

29.2

110

27.6

A6

F

42

5.9

95.2

36.1

108

44.4

A7

F

60

5.7

95.7

39.8

108

44.8

A8

M

40

5.1

88.4

30.6

107

27.8

A9

F

50

5

90

37.5

117

NA

B1

M

51

8.2

147.4

39.6

129

31.7

B10

F

79

4.9

78.2

27.9

106

42.3

B11

F

34

4.8

78.7

28.1

97

NA

B3

F

45

5.5

81.6

29.6

102

43.3

B4

F

39

5.3

99.7

30.9

103

42.1

B5

F

51

5.5

86.8

32.9

95

38

B6

F

39

4.3

112

36.6

117

41.5

B7

F

50

4.6

102.9

40.2

118

47.9

B8

M

22

5.3

117

31.7

114

NA

B9

F

60

5.2

72.5

30.2

88

NA
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Treatm
ent
Synbiot
ic
Synbiot
ic
Synbiot
ic
Synbiot
ic
Synbiot
ic
Synbiot
ic
Synbiot
ic
Synbiot
ic
Synbiot
ic
Synbiot
ic

Timepoi
nt
EndOfTr
ial
EndOfTr
ial
EndOfTr
ial
EndOfTr
ial
EndOfTr
ial
EndOfTr
ial
EndOfTr
ial
EndOfTr
ial
EndOfTr
ial
EndOfTr
ial

Subje
ct
A1

Gend
er
F

Ag
e
48

Lean_Mass
_kg
40.8

Fat_Mass
_kg
21.98

A10

F

66

40.9

30.31

A11

M

45

NA

NA

A3

F

37

52.95

52.37

A4

F

47

43.96

36.72

A5

M

43

63.95

27.78

A6

F

42

46.05

44.27

A7

F

60

47.37

40.76

A8

M

40

59.8

18.31

A9

F

50

NA

NA

Placebo

EndOfTr
ial
EndOfTr
ial
EndOfTr
ial
EndOfTr
ial
EndOfTr
ial
EndOfTr
ial
EndOfTr
ial
EndOfTr
ial
EndOfTr
ial
EndOfTr
ial

B1

M

51

90.64

46.57

B10

F

79

44.5

31.47

B11

F

34

NA

B3

F

45

B4

F

B5

Timepoi
nt
Baseline

Placebo
Placebo
Placebo
Placebo
Placebo
Placebo
Placebo
Placebo
Placebo

Treatm
ent
Synbiot
ic

BMC_
kg
1.9802
7
1.7203
5
NA

BLM.BMC
_kg
42.7845

2.6158
4
1.9774
9
3.0627
2
2.4120
3
2.3160
9
2.9595
4
NA

55.5709

94.6529

NA

4.0103
9
2.1064
6
NA

44.44

34.76

2.0451

46.492

39

51.97

33.76

55.0122

F

51

50.61

28.53

B6

F

39

58.25

43.03

B7

F

50

48.9

44

B8

M

22

NA

NA

3.0332
8
2.3247
1
2.7176
4
2.5691
4
NA

B9

F

60

NA

NA

NA

NA

Subje
ct
A1

Gend
er
F

Ag
e
48

Lean_Mass
_kg
41.38

Fat_Mass
_kg
23.93

BMC_
kg
1.9785
3

BLM.BMC
_kg
43.3602

42.6258
NA

45.9383
67.0143
48.4709
49.6947
62.792
NA

46.6281
NA

52.9441
60.973
51.4396
NA
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Synbiot
ic
Synbiot
ic
Synbiot
ic
Synbiot
ic
Synbiot
ic
Synbiot
ic
Synbiot
ic
Synbiot
ic
Synbiot
ic

Baseline

A10

F

66

42.5

41.58

Baseline

A11

M

45

NA

NA

Baseline

A3

F

37

54.37

56.73

Baseline

A4

F

47

43.64

38.12

Baseline

A5

M

43

65.33

26.08

Baseline

A6

F

42

50.02

41.79

Baseline

A7

F

60

50.13

42.65

Baseline

A8

M

40

61.7

24.9

Baseline

A9

F

50

NA

NA

Placebo

Baseline

B1

M

51

94.5

45.72

Placebo

Baseline

B10

F

79

41.6

32.1

Placebo
Placebo

Baseline
Baseline

B11
B3

F
F

34
45

NA
44.49

NA
35.57

Placebo
Placebo

Baseline
Baseline

B4
B5

F
F

39
51

55.81
51.88

42.72
33.17

Placebo

Baseline

B6

F

39

62.49

46.25

Placebo

Baseline

B7

F

50

51

49.09

Placebo
Placebo

Baseline
Baseline

B8
B9

M
F

22
60

NA
NA

NA
NA

1.7254
8
NA

44.2227

2.6275
9
1.9998
8
3.0840
3
2.3707
2
2.3355
1
2.9607
3
NA

57.0028

3.9495
6
2.1697
6
NA
2.0877
3
2.9912
2.3562
6
2.6781
5
2.4421
6
NA
NA

98.4542

NA

45.6463
68.4227
52.3916
52.4722
64.6943
NA

43.7326
NA
46.5816
58.8061
54.2397
65.1701
53.4179
NA
NA
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Table 3-S1. Body weight (g) and time (days) measurements of mice fed diet
supplemented with dairy products.

Cow Milk

Goat Milk

Camel Milk

Cow Yogurt

Goat Yogurt

Cow Yogurt Pro

Goat Yogurt Pro

Cow Cheese

0 day
15.1
14.2
16.5
14.6
15.1
14.2
12.6
15.6
15
15.7
15.5
15.4
14.5
16.5
14.2
15.5
14.8
14.7
16.9
15.3
15.6
15.7
17
17.4
16.8
17
16
15.9
17
15.8
17.2
16.8
17.3
13.6
14.3
14.8

7 day
16.4
15.9
17.9
15.9
16.7
15.1
14.6
17.6
16
17.1
16.5
16.1
15.5
17
15.8
16.1
16.1
16.3
17.7
16.1
17.9
16.1
17.4
17.4
17.4
18.5
16.7
16.7
18.1
16.5
17.9
17.3
18.9
14.5
16.1
16.5

14 day
17
16.9
19.1
17.1
17.5
16.5
15.4
17.9
16.7
17.9
17.9
17.7
16.5
17.9
16.8
17.3
17.1
17.4
18.3
16.3
18.6
17.2
18.1
18.6
18.6
18.7
17.4
17.3
19.4
17.8
19
17.7
19.1
15.3
16.9
16.9

21 day
17.5
17.6
19.3
17
17.6
16.4
15.8
18.3
17.1
18.3
17.9
17
16.3
17.4
16.5
17.1
17.1
18.5
20.2
16.4
18.9
17.2
18.4
18.7
19.1
19.2
17.5
17.7
19.5
17.7
19.2
18.9
19.8
17.1
18.5
17.5

28 day
18.7
18.1
20.4
18.2
18.5
17.9
16.3
18.5
17
18.7
18.1
18.1
16.4
18.2
18.1
18.1
17.1
18.7
19.8
16.3
18.9
18.1
18.8
19.8
19.1
20.3
18.4
18
20.5
18.6
19.3
19.4
20.3
18.3
20.1
18.4

35 day
18.8
19.2
18.2
19.5
18.7
18.9
16.9
18.9
18.1
19.5
18.4
18.4
16.3
18.6
18.3
18.4
18.2
18.9
20.8
16.9
18.9
18.2
18.9
20.1
19.7
20.9
18.7
17.5
20.7
18.8
20.3
20.1
19.6
18.1
21.1
19.5
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Cow Cheese Pro

Ctrl

16.4
15.6
16.6
15.3
15.1
16.7
14.5
16.4
17
15.7
15.4
16.6
15.5
15.8

17
15.7
18.5
16.9
15.5
17.5
15.3
16.9
17.5
16.2
15.4
17.4
16.4
16.7

17.7
16.3
18.2
16.3
16.5
18.1
16.6
17.2
18.7
16.5
17.2
17.8
17.3
17.3

18.5
17.2
18.6
17.1
17.3
18.2
17.7
18.2
18.9
17.6
17.4
19.1
18.4
18.3

18.4
17
19.2
17.8
17.3
18.1
17.5
18.6
18.6
16.7
17.3
18.1
18.4
18.2

18.6
17.4
19.3
19
17.9
18.8
18.3
18.8
19.6
16.3
16.8
17.8
18
17.6

